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ABSTRACT
HEPATOCYTE SPECIFIC GP73/GOLM1 KNOCKOUT MICE AND HUMAN
HEPATOCELLULAR CARCINOMA CELL LINES PROVIDE INSIGHTS
INTO THE POTENTIAL ROLES OF GP73 HCC SERUM BIOMARKER

Gunisha Arora, Ph.D.
Department of Biological Sciences
Northern Illinois University, 2016
Barrie P. Bode, Director

Golgi Protein – 73kDa (GP73/GOLM1) is a resident cis-Golgi Type II membrane protein that is
nearly undetectable in normal hepatocytes, but its expression increases in hepatocytes during
hepatocellular carcinoma (HCC) and its serum levels increase in patients with chronic hepatitis C
infection and HCC, yet its biological role in the liver and in the pathogenesis of HCC remains
unclear. In order to investigate possible biological roles for GP73, hepatocyte-specific GOLM1
null mice (C57BL/6) were created using the Cre-loxP system, with “floxed” GOLM1 gene exon
3 and Cre recombinase driven by the albumin promoter. Mouse genotypes were confirmed by
PCR analysis. GOLM1Fl/Fl/Cre(+) animals showed no obvious biological phenotype compared to
their Cre(-) littermates. They exhibited normal growth, behaviors, and mated successfully,
suggesting that hepatic GP73 is not vital for normal physiological function. Consistent with
clinical observations in humans, GP73 expression increased in a chemically induced model of
mouse liver fibrosis and carcinogenesis. Examination of GP73 expression in 14 human HCC cell
lines revealed that GP73 is consistently expressed in mesenchymal HCC cells (modeling
metastatic) but not in most epithelial HCC cell lines. Cell invasion assays indicated that
mesenchymal HCC with high GP73 expression were more invasive suggesting a potential role
for this protein in metastasis. Silencing in invasive mesenchymal HCC cells suggested that GP73
is necessary for enhanced cell proliferation and over-expression in a non-invasive epithelial HCC
cell line suggested that GP73 is sufficient to induce epithelial to mesenchymal transition (EMT)
and metastasis. Collectively the results suggest GP73 will serve as a potential therapeutic target
for treatment of advanced HCC and that the hepatocyte-specific GP73 knockout mice will serve
as a valuable tool to investigate the role of GP73 in HCC development.
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INTRODUCTION

HCC

Hepatocellular carcinoma (HCC) is the sixth most common type of neoplasm and is the
third leading cause of cancer-related death worldwide (Parkin, Bray, Ferlay, & Pisani, 2005).
Data from the Surveillance Epidemiology and End Results (SEER) program show that with a 5year survival rate of 17%, HCC is responsible for approximately 30,000 deaths annually and its
incidence rate has tripled in the United States since 1975 (SEER Cancer Statistics Review 19752012, NCI). HCC does not present itself until the very late stages where symptoms such as upper
abdominal pain, weight loss and yellowing of skin and eyes may occur. Primary causes of HCC
include chronic Hepatitis C or B viral (HCV or HBV) infection, alcoholism, non-alcoholic
steatohepatitis (NASH) and other environmental factors such as aflatoxin B1 exposure. It is also
found to be at least two times more common in males compared to females (Y. Zhang, Shen,
Cao, Yan, & Ji, 2015). Currently, sorafenib is the only available drug which targets specific
kinases and is recommended for treatment of advanced HCC, however, the response is poor and
of short duration (Shao, Hsu, & Cheng, 2015). It is essential that an effective target be found to
develop a chemo- or molecular therapeutic intervention with better efficacy and low toxicity to
normal cells.
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GOLM1/GP73/GOLPH2

GOLM1/GP73/GOLPH2 is a 400 amino acid, 73kDa type II cis-Golgi transmembrane
dimer protein which is highly expressed in epithelial cells of colon, stomach, prostate and
trachea. It was first found to be upregulated in a patient with giant cell hepatitis (R. D. Kladney
et al., 2000) and since then has been reported to be over-expressed in acute and chronic hepatitis
and HCC (Marrero et al., 2005). This protein has been detected in the serum of these patients and
its association with more aggressive HCC makes it an essential serum biomarker (Shi et al.,
2011). GP73 localizes to the cis-Golgi via a lumenal targeting signal and enters the late
endosome bypass pathway. This retrieval of GP73, from the sorting endosome back to the cisGolgi, is saturable upon increased expression, resulting in enhanced cycling through the transGolgi network and endosomes (Figure 1) where it is exposed to proprotein convertase such as
Furin which cleaves the ectodomain of GP73 at a conserved RVRR recognition site (Bachert,
Fimmel, & Linstedt, 2007). Accumulated GP73 ectodomain in the endosomes is released into the
serum of the patients where it can then be detected.

3

Figure 1: Upregulated cleavage and secretion of GP73. GP73, when upregulated, gets cleaved by proprotein convertase when cycling through the trans-Golgi network and the sorting endosome and is
secreted into the serum via the plasma membrane.

GP73 has a trans-membrane domain (TMD) and a coiled coil domain which are essential
to its Golgi localization and structure. Two cysteines in the coiled-coil domain are highly
conserved in GP73 orthologs and result in inter-protein disulfide bonds that help stabilize the
dimer formed by the hydrophobic interactions between the coiled-coil domains (Figure 2) (Hu,
Li, Xie, Gu, & Peng, 2011). The gene encoding GP73 in humans is located on chromosome
9q21.33 and spans 11 exons with two alternatively spliced transcript variants encoding the same
protein ("GOLM1 Golgi membrane protein 1 [Homo sapiens (human)] - Gene - NCBI", 2016).
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Figure 2: Model of GP73 dimer based on the work of (Hu et al., 2011). GP73 protein contains 5 regions,
the cytoplasmic tail, the transmembrane domain, the coiled coil domain, the flexible loop and the
conserved C-terminal acidic domain; with 5 potential N- and O-glycosylation sites and a conserved
protease cleavage site.

GP73 as a serum biomarker

Studies have revealed that GP73 expression is minimal in normal hepatocytes but is
markedly enhanced during acute and chronic hepatitis and liver cirrhosis (Iftikhar et al., 2004)
(Figure 3). It was later demonstrated that serum GP73 levels were increased in patients with
Hepatitis C virus (HCV)-related HCC in comparison with cirrhotic controls (Block et al., 2005).
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Currently the most widely used tumor biomarker for HCC, however, is serum alphafetoprotein, an embryonic protein drastically elevated in HCC which only provides a 40%
sensitivity (i.e. only 40% of patients are correctly identified as having HCC). A Kaplan-Meier
survival plot showed that increasing GP73 levels correlated with significantly poorer survival of
HCC patients (Jiang et al., 2016). Several studies have reported a higher sensitivity and
specificity (percent of patients correctly identified as not having HCC) for GP73 as a serum
biomarker for early stage HCC diagnosis (Dai et al., 2015) and while this association has been
established little is known about its role in the progression of cancer. Recent studies have
explored this role, such as in HCV secretion (Hu, Yao, Wang, Rong, & Peng, 2014), in
proliferation and migration of HCC cell lines (X. Chen et al., 2015) and in cell motility and
increased expression of (epithelial to mesenchymal transition) EMT-related proteins (Liu et al.,
2016). This study on GP73 explores these roles using different in vitro and in vivo tools.

Figure 3: Progressive upregulation of GP73 levels in chronic liver disease, which is reversible with
treatment and resolution of chronic hepatitis based on the work of (Fimmel & Wright, 2009).

MATERIAL AND METHODS

In vitro studies

HCC cell lines and cell culture

HCC is a highly heterogeneous cancer and therefore cell lines generated from these
cancers can yield divergent results. To allow reasonable conclusions from in vitro studies, HCC
cell lines have been classified based on their gene expression profiles. Microarray analysis, a
method of measuring the relative abundance of nucleic acid sequences via probe-target
hybridization, was used to characterize 19 human HCC cell lines, based on which two distinct
Groups emerged (Lee & Thorgeirsson, 2002). α-fetoprotein (AFP), normally expressed in the
endoderm of yolk sac and in fetal liver, is expressed 5-30 times higher in Group-I than in Group
II. Another defining characteristic in determining the two Groups was the expression of Ecadherin, a cell-to-cell adhesion glycoprotein, or vimentin, an intermediate filament protein.
Group I cells express E-cadherin, leading to their classification as epithelial or 'oncofetal' with
more liver-specific characteristics and the upregulation of genes involved in metastasis such as
integrin α3β1, and Group II cells express vimentin, leading to their classification as
mesenchymal (Lee & Thorgeirsson, 2002). A recent study in which 603 HCC patients' tumors'
were analyzed, three subclasses were observed. Aberrant activation of the WNT signaling
pathway was observed in the S1 subclass, proliferation as well as MYC and AKT activation in
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the S2 subclass, and hepatocyte differentiation was observed in the S3 subclass (Hoshida et al.,
2009). Based on the S1, S2, S3 system, the Group II mesenchymal cells belong to the S1
subclass and the Group I epithelial cells are divided among the S3 and S2 subclasses with Huh7
being an S2 with the characteristic activation of Myc and Akt. Thirteen HCC cell lines were
chosen for this study, six of which are Group I and seven of which belong to Group II based on
the work of Lee & Thorgeirsson (2002).
The six Group I cell lines included: HepG2, Hep3B, PLC/PRF/5 (ATCC Global
Bioresource Center, Manassas, VA), Huh1, Tong (Bryan Fuch’s lab, Massachusetts General
Hospital, Boston, MA) and Huh7 (Jake Liang, Massachusetts General Hospital, Boston, MA).
The seven Group II cell lines included: FOCUS (Jack Wand’s lab, Massachusetts General
Hospital, Boston, MA), SNU--449 (ATCC 2234), SNU--475 (ATCC 2236), SNU--387 ( ATCC
2237), SNU--423 ( ATCC 2238), SK Hep-1 (ATCC Global Bioresource Center, Manassas, VA)
and Mahlavu (Bryan Fuch’s lab, Massachusetts General Hospital, Boston, MA). All cell lines
were authenticated using STR analysis by the CORE facility at John Hopkins University. Also,
Hep3B EGFP and Hep3B GP73 (full length) transfected cell lines over-expressing GP73 were
obtained from Dr. Lorinda Wright (Hines and James A Lovell Federal Health Care Center
(FHCC)).
All cell lines were grown in monolayer format, using 4.5 mg/ml high glucose Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco; Grand Island, NY). Additives included 2 mM Lglutamine (Gibco, Grand Island, NY), 1% antibiotic/antimycotic solution (100x stock: 10,000
U/ml Penicillin G, 10,000 µg/ml Streptomycin, and 25 µg/ml Amphotericin) (ThermoScientific;
Logan, UT), and 10% triple 0.1 µm filtered fetal bovine serum (Atlanta Biologicals;
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Lawrenceville, GA) to support the specific needs of HCC cells. Cells were grown and
maintained in 25 cm2 Falcon T-flasks with 0.2 µm Vented Blue Plug Seal caps (Becton,
Dickinson and Co.; Franklin Lakes, NJ) in a humidified incubator at 37o C with 5% CO2-95% air
ratio. Cells were allowed to reach confluency (100% growth surface coverage) to allow
maximum growth and number, which were transferred via trypsin displacement (TrypLEzyme,
Gibco; Grand Island, NY) to new plates as per experimental requirements.
GP73 shRNA silencing

To suppress GP73 expression via RNA interference, a short hairpin RNA (shRNA) encoding lentiviral system was chosen because of its ability to infect both dividing and nondividing cells, sequence integration into the host genome, low toxicity, and the potential for in
vivo application (Karra & Dahm, 2010).
GIPZ shRNA plasmids

The GIPZ lentiviral shRNA plasmids used in this study are a product of GE
Healthcare Dharmacon Inc. which was developed in collaboration with Dr. Greg Hannon of Cold
Spring Harbor Laboratory and Dr. Steve Elledge of Harvard Medical School. Glycerol stocks of
E. coli containing GIPZ lentiviral plasmids with a CMV promoter sequence (an RNA
polymerase II promoter) owned and licensed by Iowa Research Foundation (Iowa City, IA) and a
proprietary nucleic acid sequence encoding a proprietary fluorescent protein, turboGFP (green
fluorescent protein), owned by Evrogen JCS (Moscow, Russia) were obtained (Figure 4). It’s
design is based on a microRNA-adapted shRNA based on miR-30 for enhanced gene silencing
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with minimal cytotoxicity (Boden et al., 2004). The six GIPZ Lentiviral Human GOLM1 shRNA
sequences (catalogue #: RHS4531-EG51280, GE Dharmacon) selected to target GP73 have
following clone IDs: V2LHS_134950, V2LHS_134954, V2LHS_234856, V2LHS_236541,
V3LHS_367298 and V3LHS_367302 referred to herein as GP1, GP2, GP3, GP4, GP5 and GP6
respectively (Table 1). The clone ID of the scrambled shRNA sequence with no sequence
homology to any known mammalian gene that served as a non-silencing (NS) negative control is
not publicly available (catalogue #: RHS4346, GE Dharmacon).

Figure 4: Detailed vector map of pGIPZ vector (Dharmacon GELifesciences, created using Geneious)
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The plasmid constructs provided in an E. coli stock (60% glycerol) were stored at -80° C.
Individual bacterial colonies were isolated by streaking cells on Luria broth (LB) (Fisher
Scientific, Fair Lawn, NJ) agar plates containing Ampicillin (100 μg/ml) and incubating the
plates for 24 hours at 37o C. Isolated colonies were picked for further expansion by inoculating
5ml Ampicillin LB broth which was then incubated for 24 hours in the shaker incubator at 37o C
to be harvested for purification of the plasmid stocks using the Wizard® Plus SV Minipreps
DNA Purification System according to manufacturer protocol (Promega, Madison, WI). The
purified plasmids were quantified using a Nanodrop 2000 Micro-Volume UV-Vis
Spectrophotometer (Thermo Scientific, Waltham, MA) and tested to confirm the presence of the
correct insert by an overnight restriction digestion using Kpn I at 37o C (Promega, Madison, WI)
and 1% agarose gel electrophoresis. Once the molecular weights of the plasmids were confirmed,
a working concentration of each plasmid was prepared by inoculating and incubating 50 ml of
low salt LB-Lennox broth (Fisher Scientific, Fair Lawn, NJ) with 8% glycerol (Fisher Scientific,
Fair Lawn, NJ) and 100 μg/ml ampicillin (Fisher Scientific, Fair Lawn, NJ) at 37° C until it
reached an OD 600 reading of 2-4 (16 hr incubation). A PureYield™ Promega Plasmid Midiprep
was used to extract and purify plasmid stocks according to the manufacturer protocol (Promega,
Madison, WI). The final elution volume for each stock was 600 μl of nuclease-free water which
was then ethanol precipitated to obtain a higher concentration. Quantification of the generated
plasmid stocks was performed using a Nanodrop 2000 Micro-Volume UV-Vis
Spectrophotometer (Thermo Scientific, Waltham, MA), and the stocks were stored at -20° C.
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Table 1: GIPZ lentiviral shRNA Sense and Antisense sequences and their targets.
Target Protein
(GOLM1)

Open Biosystems
Clone ID

Antisense Sequence (5’-3’)

Endogenous
Sequence
Targeted

NM_177937

V2LHS_134950

CAGGGAATGACAGAAACAT

1304 – 1322

NM_016548

(GP1)

ATGTTTCTGTCATTCCCTG

1312 – 1330

NM_177937

V2LHS_134954

CTACTTTATTACTGGAGTA

2276 – 2294

NM_016548

(GP2)

TACTCCAGTAATAAAGTAG

2284 – 2302

NM_177937

V2LHS_234856

GCTATTAAGTGGCTTAGAA

2058 – 2076

NM_016548

(GP3)

TTCTAAGCCACTTAATAGC

2066 – 2084

NM_177937

V2LHS_236541

GCCGAAGAGATGACTATAA

1436 – 1454

NM_016548

(GP4)

TTATAGTCATCTCTTCGGC

1444 – 1462

NM_177937

V3LHS_367298

CGAAGTGGTTTTGGATTCA

918 – 936

NM_016548

(GP5)

TGAATCCAAAACCACTTCG

926 – 944

NM_177937

V3LHS_367302

CAGTGCATCAATCAGATGA

670 – 688

NM_016548

(GP6)

TCATCTGATTGATGCACTG

678 – 696

Sense Sequence (5’-3’)

Puromycin Kill Curve

The GIPZ lentiviral vector has a puromycin resistance gene for selection of
transfected cells, therefore a dose response experiment was established to determine the
minimum antibiotic concentration required to kill all non-transfected cells. SK Hep-1, Huh1 and
Huh7 cells were plated at 5 x104 cells per well in 12-well plates and incubated overnight at 37°
C. When the cells reached 60-70% confluence the following day, the normal growth medium
was aspirated and replaced with puromycin containing medium in the following concentrations:
0.0, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 and 5.0 μg/ml. The plates were microscopically
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monitored daily to determine the concentration that kills 100% of cells within three days of
antibiotic addition. Plates were incubated and further monitored for up to a week to ensure cell
death.
Electroporation of DNA and maintenance of GP73 suppressed cell lines

The Neon® Transfection System by Invitrogen was used to optimize
electroporation of plasmid DNA in SK Hep-1 cell line by testing a range of DNA quantities: 0.5,
1, 3 and 5 μg. Five 100mm plates containing 11 ml of culture medium were allowed to sit in the
37o C 5% CO2 incubator for 2 h. SK Hep-1 cells were trypsinized, counted and harvested by
centrifugation. Using a 100 μl tip, electroporations were performed in serum-free Opti-MEM
®(Gibco, Grand Island, NY) using cell-specific protocol (Table 2) and cells were plated in the
pre-incubated 100 mm plates at a density of 5 x 105 cells per plate. Forty-eight h posttransfection, all plates were confluent and were fed puromycin-selective medium (0.5 μg/ml). An
EVOS™ FLoid™ Cell Imaging Station (Life Technologies, ThermoFisher Scientific) with a
green fluorescence channel with a 482/18 nm excitation was used to visualize turboGFP
expression in SK Hep-1 cells. Only 10-20% transfected cells survived and were allowed to grow
fourteen days post-transfection; once confluent, total cellular protein was extracted from the 100
mm plates using a 1X lysis buffer (2% SDS and 62.5 mM Tris-HCl [pH 6.8]) (both from Fisher
Scientific, Fair Lawn, NJ), and the samples were analyzed via western blot assay using human
GP73 anti-sera (obtained from Dr. Claus Fimmel, Loyola University, Chicago, IL). For longterm storage, puromycin-free medium supplemented with 10% dimethyl sulphoxide (DMSO)
was added to the transfected SK Hep-1 cells in Nunc® Cryotubes® (Sigma-Aldrich, St. Louis,
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MO), and the cell stocks were frozen at -80° C. After freezing, the cell stocks were stored in
liquid nitrogen (-196° C).
Once transfection conditions was optimized, electroporation was used for creating stable
GP73 knockdowns in SK Hep-1, Huh1 and Huh7 cells with 3 μg of GIPZ GOLM1 shRNA
plasmids listed in Table 2. Stably transfected cells were checked for plasmid expression via
visualization of GFP expression and tested for GP73 suppression via western blot. Successfully
transfected cells which showed substantial GP73 knockdown were serially passaged and
maintained in puromycin containing medium for future experiments.

Table 2: List of cell lines electroporated with GIPZ GOLM1 shRNA plasmids.

Cell line

GIPZ GOLM1 shRNA plasmids

Puromycin
concentration

Cell-specific protocol (Pulse)
Voltage

Width

Number

SK Hep-1

NS, GP1, GP2, GP3, GP4

0.5 μg/ml

870 V

35 ms

2

Huh1

NS, GP1, GP2, GP3, GP4, GP5

2 μg/ml

1275 V

40 ms

1

Huh7

NS, GP1, GP2, GP3, GP4, GP5, GP6

4 μg/ml

1275 V

40 ms

1
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Forced Over-expression of GP73

A pCMV6-XL5 vector containing human GOLM1 cDNA between the EcoRI and XhoI
restriction sites was obtained from OriGene technologies and a pCMV-Tet3G plasmid obtained
from Clontech laboratories was used as a control (Figure 6). Working concentrations of these
plasmids were prepared using the above mentioned method and 5 x 104 SK Hep-1 cells were
electroporated with 3 μg of the plasmids to obtain forced over-expression of GP73 and a pCMV
control.

Figure 5: Detailed vector map of the hGOLM1 containing pCMV6-XL5 plasmid (on the left) and a
pCMV control plasmid (on the right) Both promoters contain a pCMV promoter and an ampicillin
resistance gene.

The pCMV6-XL5 plasmid does not have a mammalian antibiotic resistance gene and
hence these transfected cells could not be selected for. The transiently transfected SK Hep-1
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lines were immediately studied (24h - 48h) for any change in their physiology and biochemistry
caused by over-expressing GP73.
Western Blot analysis

Total cellular protein samples collected in this study were analyzed using the western blot
technique. The protein concentrations were measured with a Nanodrop 2000 Micro-Volume UVVis Spectrophotometer (Thermo-Fischer) and 20 μg of the samples were prepared in 2% SDS,
10% glycerol, 62.5 mM Tris-HCl (pH 6.8), 0.050% bromophenol blue and 50 mM dithiothreitol
(DTT) (Fisher Scientific, Fair Lawn, NJ). Prepared protein samples were separated by
electrophoresis on a 4-20% Mini-PROTEAN® TGX™ precast polyacrylamide gel (Bio-Rad,
Hercules, CA) at 150 V for 45 minutes. Separated proteins were transferred from electrophoresis
gels to Immobilon-P polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA)
using the Novex® Semi-Dry Blotter at 20 V for 10 minutes.
The membranes were then incubated with a blocking buffer which, for most antibodies,
consisted of 5% bovine serum albumin (BSA) in a 1X Tris-buffered saline (Tris-base and NaCl)
(TBS-T) with 0.1% Tween-20 (all from Fisher Scientific, Fair Lawn, NJ) solution for an hour at
room temperature. However for GP73 anti-sera, blocking was done in 10% non-fat dry milk
(NFDM) in 1X TBS-T overnight at 4° C followed by three rinses (5 minutes each) with the wash
buffer (0.5% NFDM in 1X TBS-T). Most primary antibodies were prepared in the blocking
buffer (5% BSA in 1X TBS-T) (1 : 1000 dilution) and were allowed to bind specifically to the
membrane overnight at 4° C. The GP73 rabbit anti-sera was prepared in the wash buffer at 1 :
5000 dilution and allowed to bind specifically to the membrane for an hour at room temperature.
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GP73 anti-sera was prepared against full-length human GP73 protein, hence to increase the
stringency, two normal washes followed by two high-salt washes (10% 5 M NaCl in wash
buffer) were done prior to secondary antibody incubation. Most membranes were washed three
times in 1X TBS-T and then incubated for one hour at room temperature with HRP-linked
secondary antibody (1 : 2000) and anti-biotin (1 : 2000) in blocking buffer (wash buffer in the
case of GP73 blots).
For all western blot analyses, the immunoreactive bands were visualized by adding 10 ml
of chemiluminescent substrate (1X LumiGLO® and 1X Peroxide) (both from Cell Signaling,
Danvers, MA), incubating for a minute at room temperature, and imaging with a G:Box Chemiluminescence Imager (Syngene, Frederick, MD) and GeneSnap image acquisition software
(Syngene, Frederick, MD). The molecular size of the chemiluminescent bands was determined
by comparison to a biotinylated ladder (Cell Signaling, Danvers, MA) included in a proximal
lane to the experimental samples in every western blot.
All western blots were stripped and reprobed with another primary antibody used as a
loading control. After four washes with 1X TBS-T, the membrane was incubated in stripping
buffer (0.76 g Tris base, 2 g SDS, and 700 μl β-mercaptoethanol [pH 6.8]) (all from Fisher
Scientific, Fair Lawn, NJ) at 50° C for thirty minutes in a shaker incubator. After six more 1X
TBS-T washes the membranes were again blocked with 5% BSA and reprobed with an HRPlinked primary antibody serving the purpose of a loading control.
The GP73 rabbit anti-sera was obtained from Dr. Claus Fimmel (Loyola University,
Chicago, IL). Other primary antibodies such as LAT1 Ab, ASCT2 rabbit monoclonal Ab
(DSC12), E-cadherin (24E10) mAb and Vimentin (R28) Ab were obtained from Cell Signaling
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Technologies (Danvers, MA). Primary HRP-linked beta actin and COX IV (3E11) antibodies
used as loading controls, secondary HRP-conjugated goat anti-rabbit IgG antibodies and HRPlinked anti-biotin antibody, used to visualize the biotinylated ladder, were also obtained from
Cell Signaling Technologies (Danvers, MA).
Quantification of the immuno-reactive bands on western blots was done using the
ImageJ software (Rasband, 2016). Densities of quantified bands were compared to the band for
control protein sample and normalized against the loading control to obtain true relative
expression of samples.
Validation of GP73 Anti-sera

To confirm that the immuno-reactive bands appearing for GP73 anti-sera are indeed
bands for Golgi membrane protein-1, protein samples were treated with Peptide-N-Glycosidase F
(PNGaseF) (New England BioLabs), which cleaves all oligosachharides from N-linked
glycoproteins that are present in GP73 at three positions. Total cellular protein (20 μg) from
Huh7 was denatured at 100o C and treated with 8 units of PNGase at 37o C for 1 hour. DTT
treatments prior to western blots reduce disulfide bridges in the protein tertiary structure. Hence,
DTT free treatment allows dimerization of GP73 at the coiled-coil domain via disulfide bridges
at the cysteine residues. The western blot was run with normal, PNGaseF treated, DTT free, and
DTT free PNGaseF treated Huh7 protein sample and PNGaseF alone to validate the two
immuno-reactive bands observed for GP73.
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Generation of growth curves

In order to establish a relationship between cell proliferation and GP73 expression, the
rate of growth and cell proliferation were studied in GP73 suppression and over-expressing HCC
lines using XTT cell metabolic assay (TACS, Trevigen) and TALI - Image based cytometer (Life
technologies, Invitrogen). For XTT, specific numbers of cells (Table 3) were plated in
quadruplicate wells in eight 48-well plates (Corning, Corning, NY) for measuring growth and
cell proliferation for 8 days. To differentiate between growth and cell proliferation, which are
both measured by XTT through mitochondrial activity, cells were counted every 24 hours using
a cytometer. Specific numbers of cells (Table 3) were plated in all wells of a 12-well plate
(Corning, Corning, NY). Every 24 hours, cells in one well were trypsinized and 25 μl of the
resuspension was taken in a Tali® Cellular Analysis Slide for cell count and size analysis by the
image-based cytometer.
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Table 3: Cell densities plated for specific cell lines.
Cell Lines

Cell plating density (cells/ml)

Huh7 NS, Huh7 GP1, Huh7 GP2

1.5 x 104

Hep3B EGFP, Hep3B GP73FL

3 x 104

SK NS, SK GP4.3, SK GP4.5

5 x 104

Huh7 NS, Huh7 GP1, Huh7 GP2

1 x 104

Hep3B EGFP, Hep3B GP73FL

1 x 104

SK pCMV, SK hGOLM1

5 x 104

XTT

TALI

Growth Inhibition assays

Each cell line was equally plated in four 100 mm plates (Fisher Scientific). When the
cells were 80% confluent, medium with specific additives were added to the plates to inhibit
growth. Rapamycin and sorafenib were obtained from LC laboratories and working stock
concentrations were prepared using dimethyl sulfoxide (DMSO) (Fisher Scientific). Three
different mediums were prepared using the following additives: 1.12 μl DMSO, 20 nM
rapamycin and 10μM sorafenib respectively. These treatments were applied to the cells which
were then maintained in an incubator for 24 h at 37o C/5% CO2. The cells were then counted
using a hemocytometer (Hausser Scientific, Horsham, PA) and protein was extracted using 1X
lysis buffer (2% SDS, 62.5 mM Tris-HCl (pH 6.8), and 50 mM DTT) and a protease inhibitor
cocktail (Thermo Scientific). The proteins were then analyzed via western blotting techniques
using rabbit anti-human GP73 anti-sera and anti-rabbit secondary antibody.
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Transport assays

ASCT2 being a sodium dependent glutamine transporter and LAT1 being a sodium
independent leucine transporter, the initial-rate of Na+-dependent L-glutamine and Na+independent L-leucine uptake was measured by radiotracer analysis using a cluster tray method
as described in Dr. Bode's previous research (Bode et al., 2002). The cells were plated in
quadruplicates in a 24 well plate equally in all wells at a concentration of about 1 x 105 to 2 x 105
cells/ml and initial-rate measurements were taken using the radiolabeled amino acids: L-[G-3H]
glutamine or L-[G-3H] leucine. Each radiolabeled amino acid was diluted to 4 μCi/ml in the
presence of unlabeled glutamine and leucine respectively at 50 μM in sodium free (choline, Ch)
and sodium containing KRP (Krebs-Ringer phosphate) buffer. Cells were exposed to the uptake
mix in the order shown in Figure 6 for 30 seconds at room temperature, immediately followed by
three washes with cold phosphate-buffered saline solution. After drying the plates overnight,
intercellular radiolabeled glutamine or leucine was extracted by incubating the cells in a lysis
buffer (0.2% SDS and 2 N NaOH) at room temperature on a clamp shaker for half an hour. A
Perkin-Elmer TriCarb 2810 TR liquid scintillation spectrophotometer (Shelton Instruments,
Meriden, CT) was used to count the radiolabeled amino acid in 100 μl of each lysate which was
neutralized with 10 μl of 2 N HCl. The protein concentration was determined using 10 μl of the
remaining lysate with the bicinchroninic acid method (Pierce Chemical, Rockford, IL). Uptake
measurements were expressed as nmol AA•mg-1 protein•30 s-1 (Figure 7), and all measurements
were normalized to cellular protein content. Initial rate transport velocities were expressed as the
average ± standard deviation of at least four separate determinations. The transport data were
analyzed for significant differences using a t-test, with P < 0.050 considered as significant.
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Figure 6: 24-well plate layout for glutamine and leucine transport studies.

Figure 7: Calculation of transport velocity.
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Invasion assay

BD BioCoatTM MatrigelTM Invasion Chambers (BD Biosciences, Bedford, MA) were
used along with the control inserts for the invasion assay. The control inserts contain an 8 μm
pore size Polyethylene terephthalate (PET) membrane and the invasion chambers contain an 8
μm pore size PET membrane with a thin layer of MATRIGEL basement membrane. In a 24-well
format, 5 x 104 cells in serum-free medium were plated in triplicate in invasion or control inserts
and incubated for 22 hours with FBS-containing medium as the chemo-attractant in the wells
(Figure 8). The cells were maintained at 37oC in a 5% CO2 incubator. After removal of noninvading cells, the invading cells were stained using 100% methanol (Fisher Scientific) and 1%
Toluidine Blue (Sigma-Aldrich) prepared in 1% Borax (Mallinckrodt Chemical Works, St.
Louis, MO) solution. After rinsing and air drying, the membranes were cut out and mounted on
slides. For each cell line, this experiment was performed in triplicate and repeated twice. These
slides were observed using a Nikon Eclipse E-600 Transmitted Light Microscope. Cells passing
through the control chamber "C" were counted as migrating cells and cells passing through the
MATRIGEL in the invasion chamber "I" were counted as invading cells. The percent invasion
was calculated as mean number of cells migrating divided by mean number of cells invading,
and the invasion index for an experimental line was the ratio of its percent invasion with that of
its control cell line.
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Figure 8: Invasion Assay protocol. A) Control chamber and Invasion chamber differ in the

presence of a MATRIGEL that resembles basement membranes in human tissues. B) Invasion
assay. Testing the cell line's potential to digest their way through the basement membrane like
MATRIGEL towards the chemo-attractant. The invading cells are counted for comparing
metastatic potential of a cell line.

RNA Analysis

RNA extraction

RNA was extracted from tissues and cells in 1 ml of TRIzol® reagent (Ambion,
Life Technologies) followed by phase separation via the phenol-chloroform method. RNA was
precipitated from the aqueous phase, by the addition of 3 M sodium acetate and 4 volumes of
100% ethanol, followed by centrifugation at 20,000 x g for 30 minutes at 4oC. The RNA pellet
was washed with 70% ethanol, centrifuged and resuspended in DEPC (diethylpyrocarbonate,
used to inactivate RNase) water to obtain a final concentration of 4 μg/μl. Spectrophotometric
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readings of RNA (A260), as well as sample purity readings (260 nm/280 nm) were obtained using
the NanoDrop 2000 system (Thermo Fisher Scientific; Chicago, IL). RNA was stored at -70⁰ C.
cDNA preparation

cDNA was prepared using the Promega ImProm-II Reverse Transcription System
(Madison, WI). Total RNA (1µg/reaction) was combined with 0.5 µl/reaction oligo dT primer
(Promega; Madison, WI), and nuclease-free water to a final volume of 5 µl/reaction in nucleasefree, thin-walled 0.2 ml reaction tubes (Fisher Scientific). Reverse transcription master mix was
assembled using ImProm-II™ 5X Reaction Buffer 4.0 μl/reaction, 25 mM MgCl2 (final
concentration 1.5–8.0 mM) 1.2–6.4 μl/reaction, dNTP Mix (0.5 mM each dNTP) 1.0 μl/reaction,
rRNasin (Recombinant RNasin® Ribonuclease Inhibitor) (Promega, Madison, WI) 0.5 µl (20
u/reaction), nuclease-free water for a final volume of 15.0 μl/reaction, and 1X ImProm-II™
Reverse Transcriptase (Promega, Madison, WI) per 20 µl for a final volume of 5 μl RNA mix
and 15 μl master mix/reaction. Nuclease-free water was substituted for the reverse transcriptase
in –RT reactions. Annealing was done at 25o C for 5 minutes followed by first strand cDNA
synthesis (extension) at 42o C for one hour, using the Eppendorf Mastercycler gradient cycler.
geNorm Reference Gene selection

For accurate gene expression measurements, results were normalized to two fixed
reference genes selected from a cohort of 12 candidate reference genes in the geNorm reference
gene selection kit (mouse) (PrimerDesign Ltd., UK). As reference gene expression levels may
vary by tissue origin and disease type, this method was used to optimize reference genes using
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SYBR® green detection chemistry. The two selected reference genes were then used as mouse
TaqMan probes: CANX (Mm00500330_m1) and GAPDH (Mm99999915_g1) (Life
Technologies).
Quantitative real-time PCR (polymerase chain reaction)

Taqman (Applied Biosystems; Carlsbad, CA) hydrolysis probe based gene
expression analysis involved one part Taqman assay, which consisted of a pair of unlabeled PCR
primers and a TaqMan® probe specific to the target gene of interest with a 6-carboxyfluorescein
FAM™ dye at the 5’ end and a non-fluorescent minor groove binder (MGB) quencher dye
(NFQ) at the 3’ end; 10 parts Taqman master mix (Lot# 1312190), consisting of AmpliTaq
Gold® DNA hot-start activation Polymerase, a blend of dNTPs with dTTP⁄dUTP and UracilDNA Glycosylase (UDG) (to prevent mutagenesis by eliminating uracil from DNA molecules),
and a passive internal reference based on proprietary ROX™ dye; 7 parts nuclease-free water
and 500 ng of cDNA to a total volume of 20 µl per sample. The Eppendorf Realplex2
Mastercycler program was set at an initial 95o C for 10 minutes, followed by 40 cycles of 95oC
denaturing temperature for 15 seconds, and 60o C annealing/extension temperature (for all
primers) for 1 minute. Six types of samples were prepared, all run in triplicates, as required for
use with the Comparative Ct method or the ∆∆Ct method of calculating expression levels.
1. Experimental sample + Reference gene assay 1 (CANX)
2. Experimental sample + Target gene assay
3. Experimental sample + Reference gene assay 2 (GAPDH)
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4. Standard sample (control) + Reference gene assay 1 (CANX)
5. Standard sample (control) + Target gene assay
6. Standard sample (control) + Reference gene assay 2 (GAPDH)
The target gene assay used was a Taqman probe (Mm00550918_m1) with best coverage of both
GP73 transcripts (NM_001035122.2 and NM_027307.4).
The result is an expression level fold change of the target gene in the experimental sample versus
the control sample, with the data normalized to a reference gene:
R = 2 -∆∆CT = 2-(∆CT sample - ∆CT calibrator)
= 2 – [(CT sample-CT reference gene)-(CT calibrator-CT reference gene)]
Minimum Information for Publication of Quantitative Real-Time PCR Experiments
(MIQE) guidelines released in 2009 ensures the relevance, accuracy, correct interpretation, and
repeatability of an experiment and were followed in this study (Bustin et al., 2009).
In vivo studies

All animal protocols in this study received IACUC (Institutional Animal Care and Use
Committee) approval.
Generation of liver-specific GP73 knockout mice

Liver-specific GP73 knockout mice were generated by breeding Alb-Cre mice (B6.CgTg(Alb-cre)21Mgn/J) obtained from The Jackson laboratory with GP73flox/flox mice which were
generated by Dr. Lorinda Wright at Loyola University, Chicago, IL. The mouse colony was
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regularly tested for presence of other diseases by introducing sentinels (immuno-competent
mice) for a period of 6-8 weeks followed by serological and fecal examination at IDEXX
BioResearch. Both the Alb-Cre and the GP73flox/flox mice had the same genetic background and
were maintained in an animal room with easy access to water, which was acidified to prevent
diseases in the colony, and food, formulated primarily for growth and reproduction in lab mice.
GP73flox/flox genotype indicates that exon3 of GP73 (containing the start site) is flanked by LoxP
sites which are palindromic sequences and when present uni-directionally serve as sites for Cre
recombinase to target and delete the flanking sequence. Mating schemes shown in Figures 9 and
10 were used to generate the GP73flox/flox mice.

Figure 9: FLP Mating scheme for deletion of Neo cassette in conditional knockout models
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Figure 10: Genotyping guideline to obtain germline Neo deleted heterozygous mice.

Genotyping and mating scheme

Mice born from breeding experiments after a 21 day gestation period were then
genotyped using tail DNA. Pups were ear-tagged and tail snips were collected on the 16th day.
The tail snips were digested in a mixture containing 17 mM Tris (pH 7.5), 17 mM EDTA, 170
mM NaCl, 0.85% SDS and 2% Proteinase K (all obtained from Fisher Scientific) and DNA was
isolated by ethanol precipitation method and resuspended in 0.25X TE buffer (2.5 mM Tris +
0.25 mM EDTA) to obtain a final DNA concentration close to 1 µg/µl. Using the following five
primers three different genotyping polymerase chain reactions (PCR) were performed with 1 µl
tail DNA to confirm Cre-Lox presence.
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1. GolmLox1 5-CTGCAGCCCTCATCCATCTTG-3’

GT Flox

2. GolmSDL2 5’-CCAAGTCTTCTCTACTGCAGTGTC-3’

GT Flox

3. NeoDelR

5’- AACCAAACCAAACCAAGCAG-3’

Flanking Neo inser site

4. CreF

5’-GCGGTCTGGCAGTAAAAACTATC-3’

Determine Cre presence

5. CreR

5’-GTGAAACAGCATTGCTGTCACTT-3’

Determine Cre presence

20 µl reactions were prepared using 200 µM dNTPs (Promega), 0.5 mM MgCl2, 1 µM of
each primer (forward and reverse from Sigma Aldrich). The following protocols for the three
PCRs were used after gradient PCRs with annealing temperatures ranging from 58o C to 68o C
were done to establish appropriate annealing temperatures for each primer pair. Initial
denaturation was done at 98o C for 30 seconds followed by addition of 0.4 units of Phusion HighFidelity DNA polymerase (Thermo Scientific) at 72o C.

Table 4: PCR programs for the three different primer pairs.

PCR cycle

CreF/CreR

LoxP/NeoDelR

LoxP/SDL2

Denaturation

98o C

10 seconds

98o C

10 seconds

98o C

10 seconds

Annealing

62o C

30 seconds

68o C

30 seconds

66o C

30 seconds

Extension

72o C

30 seconds

72o C

1 minute

72o C

30 seconds

Cycles

30

34

32

30
On day 21, the pups were weaned (males and females separated) followed by a 21 day
period to sexual maturity when new breeding pairs were set. Genotypes shown in figure 11 were
obtained from breeding experiments. Genetic background of these mice can affect phenotyping
and histology, hence the mice generated were back-crossed several generations (Figure 12) to
obtain mice that only differ in the presence of Cre. Alb-Cre+ GP73fl/fl experimental mice and
Alb-Cre-/- GP73fl/fl control mice were thus obtained.

Figure 11: Genotyping guideline and mating scheme to obtain Liver-specific GP73 knockout.
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F1

F2

F3

F4

F5
Figure 12: Five generations of successive back-crosses to obtain identical genetic backgrounds.

Tissue isolation and blood collection

Experimental and control genotyped male and female mice 11 to 13 months of age were
weighed and then euthanized by CO2 inhalation according to AVMA guidelines (. Blood was
collected by cardiac puncture using a 22 gauge needle and placed in a BD Vacutainer® serum
collection tube. Necropsies were performed on all mice. A macroscopic examination of the
internal organs was done to check for abnormalities. The right liver lobe and right kidney were
snap frozen in liquid nitrogen for RNA and protein extraction and the middle liver lobe and left
kidney were placed in 4% formalin solution for histology.
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Tissue processing for RNA and protein extraction

The snap frozen liver and kidney tissues were homogenized in liquid nitrogen using a
mortar and pestle. The powdered tissue was then divided into two tubes, 3 parts for RNA
extraction and 1 part for protein extraction and kept on dry ice. For RNA, 1 ml of TRIzol®
reagent were added and kept at room temperature for 1 minute. For protein, 500 µl of 1X lysis
buffer was added and held on ice. Both the RNA and protein samples were vortexed at high
speed for 1 minute. RNA samples were further processed by phenol-chloroform phase separation
and ethanol precipitation of RNA. Protein samples were sonicated for 2 minutes to fully dissolve
the proteins in solution. RNA and protein concentrations were measured using the Nanodrop
spectrophotometer system. Final RNA concentrations were adjusted to 4 µg/µl using DEPC
water and then stored at -80o C. Protease inhibitor cocktail (1% final) was added to the protein
samples, which were vortexed and stored at -80o C for future investigation.

GP73 AND SUSTAINED CELL PROLIFERATION

Introduction

High levels of GP73 expression are linked to sustained proliferation of hepatocytes.
Hepatocellular carcinoma cell lines behave similarly to developing liver cells in terms of their
expression of GP73 as opposed to a regenerating liver which represents unsustained proliferation
and does not express high GP73 (Figure 13). An MDR2 knockout mouse model of HCC shows
enhanced GP73 expression at precancerous stages compared to its age-matched controls (Figure
14).

Figure 13: GP73 expression profile of Regenerating liver (on the right) and Developing Embryonic
Liver (on the left) of mice. Counts on the Y-axis indicate dChip normalized modeled signal value. Data
generated using the Gene Expression Omnibus at the National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/geo/
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Figure 14: GP73 expression profile of mouse models of Hepatocellular carcinoma at precancerous
stages (on the right) compared to age matched controls (on the left). Counts on the Y-axis indicate
Microarray Suite version 5.0-calculated signal intensity. Data generated using the Gene Expression
Omnibus at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/).

The role played by GP73 in proliferation and viability of cancer cells was also shown by
a study involving GP73 silencing in hepatoma cell lines. An increase in the percentage of cells in
the G0/G1 phase and a decrease in the percentage of cells in G2/M phase were seen in GP73
silenced hepatoma cell lines. A decrease in GP73 not only inhibited cell proliferation but also led
to apoptosis in HepG2 and Bel7402 hepatoma cell lines as shown by a reduction in Bcl2/Bax
ratio, an increase in cytoplasmic cytochrome c and the appearance of apoptotic bodies and
nuclear fragmentation (Y. L. Zhang et al., 2014). Using recombinant peptides, recent studies
have determined that the C-terminus of GP73 plays an important role in cell proliferation and
targeting the C-terminal using monoclonal antibodies inhibited liver cancer cell proliferation in a
time- and dose-dependent manner (X. Chen et al., 2015). However, a recent study on knockdown
of GP73 has shown that GP73 silencing had no significant effect on cell cycle progression, but
did affect cell viability and colony formation (Liu et al., 2016). Thus, results to-date on the role
of GOLM1 in cell proliferation remain equivocal and unresolved.
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Influence mTOR Activity on GP73

The receptor tyrosine kinase RTK/PI3K/Akt/mammalian target of rapamycin
mTOR pathway plays a crucial role in regulating cell growth, proliferation and metabolism and
is the most frequently activated pathway in HCC (Wang, Jin, Jin, & Wang, 2014). A recent study
in human HCC tissues showed high levels of GP73 and active mTOR coexisting in more than
half of the patients when compared to adjacent tissues. PTEN, an inhibitory component of the
mTOR pathway, when silenced in MEFs (mouse embryogenic fibroblasts) resulted in an increase
in GP73 expression which was reversible by treatment with rapamycin, the mTOR inhibitor (X.
Chen et al., 2015). This upregulation of GP73 by mTOR complex1 also served as a predictive
marker for the response of tumor cells to rapamycin. Thus, mTOR appears to regulate GP73
expression.
Role of mTOR in HCC

mTOR is an atypical serine threonine kinase that regulates cell growth by
integrating signals from nutrients and growth factors. It forms two distinct complexes named
mTOR complex1 (mTORC1) and mTOR complex 2 (mTORC2), the first complex contains
regulatory-associated protein of mammalian target of rapamycin (raptor) and is rapamycin
sensitive (Kim et al., 2002), however the second complex contains rapamycin-insensitive
companion of mTOR (rictor) (Sarbassov et al., 2004). The mTOR/Raptor complex
phosphorylates p70 ribosomal protein S6 kinase 1 (S6K1) and eIF4E-binding protein 1 (4EBP1), which in turn promotes protein synthesis (Hara et al., 1998). mTORC1, in addition to
altering protein synthesis, strongly affects gene transcription, via regulating the activity of
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specific transcription factors and other alternate processes such as epigenetic mechanisms or by
altering RNA stability or degradation (Laplante & Sabatini, 2013). Deregulation of mTORC1
results in its hyperactivation which is associated with many diseases such as HCC, obesity, and
some neurodegenerative dieseases. When active, mTOR triggers cell growth and proliferation by
promoting protein synthesis, lipid biogenesis, and metabolism, and by reducing autophagy.
Phase I/II trials have shown that everolimus, a second-generation mTORC1 inhibitor, hinders
disease progression in patients with advanced HCC (Ashworth & Wu, 2014).
Activation of mTOR by Amino Acid Transporters

Amino acids such as leucine and arginine activate mTORC1 and must be
present for any upstream signal, including growth factors, to activate mTORC1(Hara et al.,
1998). Since mTORC1 activity is dependent on the availability of amino acids, ASCT2 and
LAT1 - amino acid transporters upregulated in primary liver cancers and HCC cell lines (Fuchs
& Bode, 2005) - function upstream of mTORC1 to allow the cell to sense amino acid availability
and launch an anabolic response such as increased translation and growth, or when amino acid
are limiting, a catabolic response such as autophagy. It has been shown that active uptake of
extracellular GLN via ASCT2 coupled with its exchange of essential amino acids (EAA) like
leucine via LAT1 leads to the suppression of autophagy through mTORC1 signaling (Nicklin et
al., 2009). Work from our lab showed that silencing ASCT2 elicits apoptotic responses and
inhibition of mTORC1 signaling, further indicating the relevance of this transporter with
mTORC1 signaling (Fuchs, Finger, Onan, & Bode, 2007; Fuchs, Perez, Suetterlin, Chaudhry, &
Bode, 2004). Tumor cells selectively regulate nutrient transporters to support their rapid growth;
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therefore ASCT2 and LAT1 play an essential role in understanding tumorigenesis (Ganapathy,
Thangaraju, & Prasad, 2009).
Role of Glutamine in HCC

Glutamine, the most abundant non-essential amino acid in blood at concentrations
of 0.6-0.9 mmol/L, has been reclassified as “conditionally essential” during critical illness as it is
the major oxidizable substrate for tumor cells (Lacey & Wilmore, 1990). Tumor cell survival and
proliferation requires rapid synthesis of macromolecules including lipids, proteins and
nucleotides (DeBerardinis et al., 2007). To meet these needs most cancer cells rely on a
phenomenon termed as "the Warburg effect". Glycolysis in the presence of abundant oxygen
resulting in abundant production of lactate is typical of this state, and though the tricarboxylic
acid cycle (TCA) may be active at this time, it is characterized by an efflux of substrates for use
in biosynthetic pathways such as fatty acid synthesis (Vander Heiden, Cantley, & Thompson,
2009). This relies on the activation of pathways to generate reductive power (NADPH) and to
restore oxaloacetate for continued TCA cycle function. Both needs are met by a high rate of
glutamine metabolism which provides a carbon source for biosynthetic precursors and sustains
the energetic and nitrogen needs of those cells (Aledo, 2004).
Scientific Aims

GP73 is not expressed in the regenerating liver as much as a developing liver indicating
its relationship to sustained proliferation of cells and an important role downstream of mTOR
and amino acid uptake. It was hypothesized that GP73 silencing or over-expression impacts cell
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proliferation by suppressing or enhancing amino acid uptake respectively, and that GP73
expression could be affected by growth inhibition treatments. The following specific aims were
executed to test this hypothesis:
1. To assess the necessity and sufficiency of GP73 for the viability of HCC cells by studying
growth and cell proliferation in GP73 over-expressing and GP73 knockdown cell lines
2. To measure the effect of growth inhibition via rapamycin and sorafenib treatment on GP73
expression.
3. To determine the uptake of glutamine and leucine and expression of amino acid transporters ASCT2 and LAT1 in GP73 over-expressing and knockdown HCC cell lines.
Results

Validation of GP73 anti-sera

Two immuno-reactive bands were observed on all GP73 western blots. To confirm their
identity PNGase treatment was performed to remove N-glycosylation and protein samples were
prepared in presence or absence of DTT were compared via western blotting (Figure 15).
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Figure 15: Western blot for validation of GP73 anti-sera showing glycosylated GP73 at approximately
140 kDa, unglycosylated GP73 at 73 kDa and the GP73 dimer at 100-120 kDa.

GP73 Knockdown

Lentiviral shRNA silencing of GP73 was done in a Group I cell line - Huh7 and a Group
II HCC line - SK Hep-1, both of which normally express high levels of GP73. A representative
cell line from both the Groups was examined to understand the complexity behind the role of
GP73 in each HCC cell type. Using different plasmid DNA concentrations, electroporations were
optimized in SK Hep-1 cells. Cells electroporated with 3 or 5 μg DNA survived 0.5 μg/ml
puromycin selection pressure. Results from western blot analysis of the two cell lines established
3 μg as the optimal DNA concentration for transfecting GIPZ plasmids (Figure 16). Both SK
Hep-1 and Huh7 were transfected with other GIPZ GOLM1 shRNA plasmids to generate GP73
suppressed SK Hep-1 and Huh7 lines (Figure 17) for further studies.
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Figure 16: Prominent GP73 suppression observed in SK GP1 and SK GP4.3. A) Western blot
analysis to confirm GP73 suppression in SK Hep-1 cell line with β-actin as a loading control. On the
right, GP4.3 and GP4.5 represent the different concentrations of the GP4 plasmid used for electroporation
(3 and 5 μg). B) Image J analysis of bands in A), to normalize expression of GP73 protein to the

loading control.

B

1.40

Relative Adjusted Densities

A

1.20
1.00
0.80
0.60
0.40
0.20
0.00

Figure 17: Prominent GP73 suppression observed in Huh7 GP1 and GP3. A) Western blot analysis
to confirm GP73 suppression in Huh7 cell line with β-actin as a loading control. B) Image J analysis of
bands in A), to normalize expression of GP73 protein to the loading control.
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GP73 Over-expression

GP73 over-expressing Group I cell line Hep3B obtained from Dr. Lorinda Wright
(Loyola School of Medicine, Chicago) were examined by protein extraction and western
blotting. Hep3B EGFP, the control cell line was also provided, which expressed enhanced green
fluorescent protein similar to the experimental cell line Hep3B GP73. A Group II HCC line, SK
Hep-1 transfected transiently with pCMV XL5 hGOLM1 plasmid was also studied in
comparison to a control containing an empty vector with the same promoter, pCMV. As SK
hGOLM1 was a transient transfection, all further studies were performed within a week of
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electroporation (Figure 18).
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Figure 18: Stable and prominent GP73 over-expression observed in Hep3B and transient and little
GP73 over-expression observed in SK Hep-1. A) Western blot analysis to confirm GP73 overexpression in Hep3B and SK Hep-1 cell lines compared to their respective controls with β-actin as a
loading control. B) Image J analysis to confirm relative over-expression of GP73 compared to the controls
and normalized to the loading control β-actin.
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Cell Proliferation and GP73

Cell proliferation was analyzed by plotting growth curves for all transfected cell lines and
their controls. These growth curves were either based on proliferation measurements from TALI
cytometer for direct cell counts or an XTT metabolic/calorimetric assay by absorbance at 490
nm, with the background absorbance at 630 nm subtracted (Figures 19 - 22).
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Figure 19: Silencing GP73 in a Group I cell line Huh7 enhances cell proliferation. Graph comparing
cell proliferation in Huh7 control and GP73 knockdown lines via an XTT assay with standard deviations
from quadruplicate readings.

43
1200000

1000000

Cells / ml

800000

SK-NS
600000

SK-GP4.3
SK-GP4.5

400000

200000

0

0h

24 h

48 h

72 h

96 h

Figure 20: Silencing GP73 in a Group II cell line SK Hep-1 reduces cell proliferation. Graph
comparing cell proliferation in SK Hep-1 control and GP73 knockdown cell lines using a TALI cytometer
to count the number of cells in a ml.
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Figure 21: Transiently over-expressing GP73 in a Group II cell line SK Hep-1 enhances cell
proliferation late in culture. Graph comparing cell proliferation in SK Hep-1 control and GP73 overexpressing cell line using a TALI cytometer to count the number of cells in a ml.
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Figure 22: Stable over-expression of GP73 in a Group I cell line Hep3B results in slightly delayed
cell proliferation. Graph comparing cell proliferation in Hep3B control and GP73 over-expressing cell
line via an XTT assay with standard deviations for the quadruplicate readings.

Growth Inhibition by Rapamycin and Sorafenib

When 80% confluent, medium on the three 100 mm plates prepared for each cell line
were changed to 11 ml normal medium containing 1.12 μl of DMSO, 200 μM rapamycin or 100
nM sorafenib. After 24 hour treatment, transfected cells and their respective controls were
counted (Figure 23) and proteins were extracted in 1X lysis buffer containing 1% protease
inhibitor. Protein samples were then subjected to western blotted analysis to assess changes in
GP73 expression due to sorafenib or rapamycin treatment (Figure 24 and 25). The vehicle for
rapamycin and sorafenib was DMSO, which was added to the control plate.
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Figure 23: Rapamycin and sorafenib treatment result in growth inhibition. Graph comparing number
of cells 24 hours after treatment with rapamycin and sorafenib with DMSO as control vehicle.

Figure 24: Diminished GP73 expression due to sorafenib treatment in both Huh7 control and GP73
knockdown cell line. Western blot comparing GP73 expression in Huh7 GP73 knockdown cell line upon
growth inhibition by rapamycin (Rap) or sorafenib (Sor) (24 h Rx) with β-actin as a loading control.
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Figure 25: Diminished GP73 expression due to sorafenib treatment in Hep3B GP73 over-expressing
cell line. A western blot comparing GP73 expression in Hep3B GP73 over-expressing cell line upon
growth inhibition by rapamycin (Rap) or sorafenib (Sor) (24 h Rx) with β-actin as a loading control.

Amino acid uptake

Glutamine and leucine uptake in cells transfected with GP73 were analyzed because of
the close relationship of growth to GP73. Being a Golgi protein, it can be hypothesized that
GP73 plays a role in trafficking of amino acid transporters. Amino acid transport was measured
and reported in units of nmol AA•mg-1 protein•30 s-1, and standard deviations were calculated
from quadruplicate determinations. Leucine's role in regulation of mTOR (Lynch, 2001) and the
high rate of glutamine metabolism in HCC (Hensley, Wasti, & DeBerardinis, 2013) make these
two amino acids essential for this study. Our results show that glutamine uptake was enhanced
when GP73 was silenced, and reduced when GP73 was over-expressed in a Group II cell line SK
Hep-1; indicating a correlation between GP73 and glutamine uptake in Group II cell lines. On
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the other hand, reduced glutamine uptake was observed in both GP73 silencing and overexpressing Group I cell lines, Hep3B and Huh7. A t-test was performed for each comparison to
assess the significance of the difference in glutamine or leucine transport. (Figures 26 - 33)
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Figure 26: GP73 silencing in a Group II cell line results in enhanced glutamine uptake. Graph
comparing glutamine (Q) uptake in SK Hep-1 GP73 knockdown lines to control SK NS with standard
deviations from 3 repeats. * indicates that p-value is < 0.050 and thus the difference can be considered
significant.
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Figure 27: Transient over-expression of GP73 in a Group II cell line results in diminished
glutamine uptake. Graph comparing glutamine (Q) uptake in SK Hep-1 GP73 over-expressing line to
control SK-pCMV with standard deviations from 3 repeats. *indicates that the p-value is < 0.050 and thus
the difference can be considered significant.
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Figure 28: GP73 silencing in a Group I cell line results in diminished glutamine uptake. Graph
comparing glutamine uptake in Huh7 GP73 knockdown lines to control Huh7 NS with standard
deviations from 3 repeats. * indicates that the p-value is < 0.050 and thus the difference can be considered
significant.
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Figure 29: Over-expression of GP73 in a Group I cell line results in diminished glutamine uptake.
Graph comparing glutamine (Q) uptake in Hep3B GP73 over-expressing cell line to control Hep3B EGFP
with standard deviations from 3 repeats. * indicates that the p-value is < 0.050 and thus the difference can
be considered significant.
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Figure 30: GP73 silencing in a Group II cell line results in enhanced leucine uptake. Graph
comparing leucine (L) uptake in SK Hep-1 GP73 knockdown lines to control SK NS with standard
deviations from 3 repeats. * indicates that p-value is < 0.050 and thus the difference can be considered
significant.

50

nmol L • mg -1 protein • 30 s -1

1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
SK-pCMV

SK-hGOLM1

Figure 31: Transient over-expression of GP73 in a Group II cell line does not change leucine
uptake. Graph comparing leucine (L) uptake in SK Hep-1 GP73 over-expressing line to control SK
pCMV with standard deviations from 3 repeats. p-value > 0.050 and thus the difference cannot be
considered significant.
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Figure 32: GP73 silencing in a Group I cell line results in enhanced leucine uptake. Graph comparing
leucine (L) uptake in Huh7 GP73 knockdown lines to control Huh7 NS with standard deviations from 3
repeats. * indicates that the p-value is < 0.050 and thus the difference can be considered significant.
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Figure 33: Over-expression of GP73 in a Group I cell line results in enhanced leucine uptake. Graph
comparing leucine (L) uptake in Hep3B GP73 over-expressing cell line to control Hep3B EGFP with
standard deviations from 3 repeats. * indicates that the p-value is < 0.050 and thus the difference can be
considered significant.

Expression of amino acid transporters ASCT2 and LAT1

The expression of major transporters of amino acids, glutamine and leucine, in HCC cell
lines were examined for changes in amino acid uptake due to the availability of transporters on
the membrane or need for glutamine i.e. due to physiological reasons, or due to the expression of
ASCT2 and LAT1 i.e. due to biochemical reasons. Proteins extracted from the GP73 silenced or
over-expressing transfected lines were assessed for ASCT2 and LAT1 expression via western
blot analysis versus their respective controls. The amino acid transport results were then
compared and contrasted with the western blot images (Figures 34 - 35).
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Figure 34: ASCT2 expression in GP73 manipulated cell lines, increases with GP73 silencing of a
Group II cell line and GP73 over-expression of a Group I cell line. On the other hand, ASCT2 expression
is diminished with GP73 over-expression of a Group II cell line and GP73 silencing of a Group I cell line.
A) Western blot comparing ASCT2 expression in all GP73 transfectants with GAPDH as a loading
control. B) Image J analysis comparing relative expression of ASCT2 in each transfected cell line with its
respective control with band intensities normalized to the loading control GAPDH.
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Figure 35: LAT1 expression in GP73 manipulated cell lines, increases with GP73 silencing and overexpression of a Group II cell line and GP73 over-expression of a Group I cell line. On the other hand,
LAT1 expression is diminished with GP73 silencing of a Group I cell line. A) Western blot comparing
LAT1 expression in all GP73 transfectants with COX IV as a loading control. B) Image J analysis
comparing relative expression of LAT1 in each transfected cell line with its respective control with band
intensities adjusted to the loading control COX IV.
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Conclusions

Human GP73 predicted secondary structure shows the presence of several
phosphorylations, myristoylations and three N-linked glycosylations which increase the apparent
molecular weight on a western blot. Two cysteines in the coiled coil domain can potentially lead
to stabilization of a dimer due to disulfide bridges which are broken down during western
blotting by addition of DTT. The results in Figure 15 indicate that GP73 dimerization requires
the presence of N-linked glycosylation in the protein as PNGase treated DTT free sample
showed no GP73 dimer formation in contrast to the DTT free sample which was not treated with
PNGase.
Six unique regions of GP73 mRNA transcript were targeted by shRNA and from each set
of transfections two best knockdowns for each cell line were selected for further studies. In case
of SK Hep-1 cell line, SK GP1 and SK GP4.3 and in case of Huh7 cell line, Huh7 GP1 and Huh7
GP3 showed the most suppression of GP73 (Figure 16 and 17). Hep3B GP73 and SK hGOLM1,
both over-expressed full length GP73 (amino acids 1-400) compared to their controls (Figure
18), and served as in vitro tools for examining the impact of GP73 over-expression on different
functions in HCC.
GP73 silencing enhanced cell proliferation in a Group I cell line Huh7 (Figure 19), but
diminished cell proliferation in a Group II cell line SK Hep-1 (Figure 20). Furthermore, overexpressing GP73 in a Group I cell line Hep3B (Figure 22) delayed cell proliferation at early
stages but marginally enhanced proliferation late in Group II cell line SK Hep-1 (Figure 21).
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GP73 might therefore play substantially different roles in the two types of HCC cells that
correlate with early (Group I) and late stages (Group II) of HCC.
Sorafenib is the only FDA approved drug for treatment of HCC which may inhibit tumor
growth by a dual mechanism, acting either directly on the tumor (through inhibition of receptor
tyrosine kinases and B-Raf) and/or on tumor angiogenesis (through inhibition of vascular
endothelial growth factor receptors) (Adnane, Trail, Taylor, & Wilhelm, 2006). The results in
Figures 23 - 25 indicate that GP73 might play a role in these mechanisms. GP73 suppression
secondary to sorafenib treatment was more prominent than suppression by rapamycin.
Unexpectedly, rapamycin did not reduce GP73 expression - these results differ from previously
published research where the same concentration (20 nM) of rapamycin was used for the same
period of time (24 hours). If mTOR is indeed upstream of GP73 expression, inhibition of mTOR
activity by rapamycin should have suppressed GP73 expression. However, GP73 expression in
Huh7 NS and Hep3BGP73 lines does appear to enhance the impact of rapamycin on cell death or
the inhibition of growth compared to GP73 silenced lines such as Huh7 GP1 and Hep3B EGFP,
suggesting that mTORC1 and GP73 may be linked.
Cancer cells are known to be avid glutamine consumers and studies have suggested that
glutamine may act not only to promote growth, but also to suppress apoptosis and initiate a stress
response. Due to this enhanced requirement of glutamine, a switch in transporter activity takes
place from System N transporters, such as SNAT3 and SNAT5 which work in the perivenous
and periportal regions of the liver, respectively, to maintain systemic glutamine levels (Baird et
al., 2004), to System ASC transporters, such as ASCT2 which accounts for the 10- to 20-fold
increase in glutamine uptake (Bode et al., 2002). Contrary to what we expected, GP73 over-
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expression in both Group I and Group II cell lines reduced the uptake of glutamine (Figures 27
and 29). This decrease in glutamine uptake could be caused by ASCT2 repression in GP73 overexpressing Group II cell line SK Hep-1 (Figure 34). However, enhanced ASCT2 expression in
the face of reduced glutamine uptake by Hep3B GP73 over-expressing cells likely indicates a
diminished trafficking of ASCT2 to the plasma membrane. GP73 silencing in the Group I cell
line Huh7 resulted in diminished ASCT2 expression (Figure 34) and glutamine uptake (Figure
28), and in the Group II cell line SK Hep-1 resulted in enhanced ASCT2 expression (Figure 34)
and glutamine uptake (Figure 26). These results indicate a negative correlation of GP73
expression and glutamine uptake or ASCT2 expression in Group II cell lines.
Glutamine in combination with leucine activates mTORC1 by enhancing glutaminolysis
and α-ketoglutarate production (Duran et al., 2012). As mTOR is known to effect GP73
expression, hence it was assessed whether there is a feedback loop between GP73 expression and
leucine uptake. GP73 silencing in Group I cell line Huh7 resulted in diminished LAT1
expression and in Group II cell line SK Hep-1 resulted in enhanced LAT1 expression (Figure 35)
but with increased leucine uptake in both cases (Figures 30 and 32). GP73 over-expression in
Group I cell line Hep3B resulted in enhanced LAT1 expression (Figure 35) and leucine uptake
(Figure 33), and in Group II cell line SK Hep-1 resulted in enhanced LAT1 expression (Figure
35) but no change in leucine uptake (Figure 31). These results indicate a correlation of GP73 and
LAT1 expression in Group I cell lines.

GP73, METASTASIS AND INVASION

Introduction

GP73 has long been suspected to have a role in epithelial mesenchymal transition (EMT)
resulting in enhanced invasiveness of cancer. Deletion of GP73 increases WT1 expression (Li et
al., 2012), a tumor suppressor whose knock-down is known to induce EMT, and increase
migration and expression of N-cadherin (Takeichi, Nimura, Mori, Nakagami, & Kaneda, 2013).
Role of GP73 in EMT has also been shown, by over-expression and suppression of GP73 in
HCC cell lines followed by comparison of the metastatic potential of transfected GP73 overexpressing HCC lines (metastasized to the lungs) to non-transfected lines (did not metastasize),
that GP73 influences the metastatic process (X. Chen et al., 2015). A study in esophageal
squamous cell carcinoma patients shows that aberrant GOLM1-MAK10 RNA levels correspond
with enhanced lymph node metastasis (H. Zhang et al., 2013) and another study in prostate
cancer showed that the tumor-suppressive microRNA-143/145 cluster targets GP73 resulting in
inhibition of cell migration and invasion (Kojima et al., 2014). There is a close relationship
between EMT and invasiveness, and analysis of EMT markers in HCC specimens showed a
negative correlation of GP73 with E-cadherin, an epithelial marker, and a positive correlation
with vimentin, a mesenchymal marker (Bao et al., 2013). This study also showed significant
correlation of GP73 with vascular invasion. Upregulated GP73 expression was found in HCC
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tissues with metastasis (Jiang et al., 2016). A recent study identifies CD44 and MMP7 as critical
effectors for GP73 enhanced cell proliferation and transformation (X. Chen et al., 2015). These
proteins have been reported to be involved in the metastasis of several different cancers,
including HCC (L. Chen, Li, Li, Wang, & Xie, 2013; Hou, Zou, Ge, Shen, & Wang, 2012).
GP73 is over-expressed in androgen-responsive Leydig cell tumor and prostate cancer and
bioinformatic analysis (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit) of the
GOLM1 promoter region showed that it spans six androgen responsive elements (H. Zhang et
al., 2013). The significance of androgen receptors has been established in HCC due to its
association with local cancer cell infiltration, in which MMP-2 and MMP-9 may play important
roles in the HCC microenvironment to increase invasion and metastasis (Y. Zhang et al., 2015).
GP73 could possibly play a role downstream of androgen receptors, with its effectors being
matrix metallo-proteinases thereby promoting migration and invasion of HCC in males - in
whom the annualized rate of HCC is twice as high as that in females (Hayat, Howlader,
Reichman, & Edwards, 2007). Another recent study on knockdown of GP73 has shown that
GP73 silencing inhibits cell motility and migration in vitro (Liu et al., 2016). Thus GP73 appears
to be necessary for HCC metastasis.
Scientific Aims

Correlation of GP73 with metastasis and vascular invasion has been repeatedly
established in HCC patients. GP73 correlation with EMT markers and inhibition of cell
migration and invasion due to its knockdown has been shown in HCC cells. Thus, it is
hypothesized that the more metastatic/mesenchymal HCC lines express higher GP73 compared
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to epithelial like HCC lines and GP73 over-expression and knockdown has a direct effect on
invasiveness and migration of the cell line in vitro.
The specific aims proposed to test this hypothesis were:
1. To compare GP73 expression in a panel of Group I and Group II HCC lines.
2. To compare the migration and invasiveness and the expression of E-cadherin and vimentin in
the panel of 13 different HCC lines.
3. To study any changes in invasiveness due to GP73 silencing and over-expression in Group II
and Group I cell lines.
Results

HCC lines, EMT markers and Invasiveness

A comprehensive analysis of GP73, E-cadherin and vimentin expression was performed
in the 13 different HCC lines belonging to Group I epithelial-like and Group-II metastatic/
mesenchymal cell lines to assess the relationship of GP73 to EMT markers in Group I and Group
II cell lines (Figures 36 - 38).
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Figure 36: GP73 expression in HCC lines. Group I epithelial HCC cells express low levels of GP73
with the exception of Huh1 and Huh7, and Group II mesenchymal/metastatic cells express high levels of
GP73. A) Western blot for expression of GP73 in all 13 Group I and Group II HCC lines with β-actin as a
loading control. B) Image J analysis of bands in A) comparing GP73 expression in Group I and Group II
HCC lines normalized to the loading control β-actin.
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Figure 37: E-cadherin expression in all HCC lines. All Group I cell lines express E-cadherin whereas
Group II cell lines do not. Western blot for expression of E-cadherin in all 13 Group I and Group II HCC
lines with β-actin as a loading control.
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Figure 38: Vimentin expression in all HCC lines. All Group II cell lines express vimentin whereas
Group I cell lines do not, except for Tong. Western blot for expression of E-cadherin in all 13 Group I and
Group II HCC lines with β-actin as a loading control.

Next, the metastatic phenotype of Group I vs II HCC lines was assessed by invasion
assay, comparing the number of cells migrated (C) and invaded (I) across a membrane with a
serum gradient.
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Figure 39: Microscopic images of invading HCC lines. Group II cells show higher number of invading
cells compared to Group I cells except for Huh7. Microscopic images of invading Group I (HepG2,
Hep3B and Huh7) and Group II (Focus and Mahlavu) cells (stained dark) at 40X magnification.

Figure 40: Group II cells have higher number of migratory and invading cells compared to Group I
cells. The bar graph shows the number of cells invading on the left front (Group I) and right front (Group
II) and number of cells migrating on the left back (Group I) and right back (Group II).
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GP73, EMT and Invasiveness

While the previous data were correlative, the ability of GP73 expression alone to be sufficient or
necessary to change metastatic phenotype was tested by examining the influence of GP73 on the
expression of E-cadherin and Vimentin. GP73 transfected lines were tested for EMT markers and changes
in invasiveness in comparison to their controls to assess the role of GP73 in this process.

Figure 41: E-cadherin expression in GP73 manipulated cell lines, decreases with GP73 overexpression and increases with GP73 silencing in Group I cell lines. Western blot comparing E-cadherin
expression in all GP73 transfectants with β-actin as a loading control.
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Figure 42: Vimentin expression in GP73 manipulated cell lines, increases with GP73 over-expression
in Group II cell line. Western blot comparing vimentin expression in all GP73 transfectants with β-actin
as a loading control.

Invasion assays

All the GP73 transfected Group I and Group II cell lines were examined for
changes in invasiveness and cell migration, each of which requires a different biochemistry and
cell physiology. Cell invasiveness requires a cell to be able to digest its way through the
basement membrane and invade the neighboring tissues using enzymes like matrix
metalloproteases and cell migration is a central process involved in wound healing and immune
responses which requires the maintenance of cell polarity via microtubules and filamentous
actins (Ridley et al., 2003). Several matrix metalloproteases such as MMP7 are shown to be
correlated to GP73 expression, and thus GP73 might play an important role in regulating
invasiveness of a cell.
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On the microscopic images (Figures 43 - 46) of cell migrating (indicated as "C") and
cells invading (indicated as "I"), the pores in the PET membrane can be seen as white and the
cells as stained dark. A 100 μm scale bar is present in each image that depicts the physical scale
of the cells in the image. Results based on the invasion assays show that silencing GP73 in both
Group I cell line Huh7 (Figure 43) and Group II cell line SK Hep-1 (Figure 45). Forced overexpression of GP73 resulted in unchanged invasiveness in Group II cell line SK Hep-1 (Figure
44) but increased invasiveness in Group I cell line Hep3B (Figure 46).

Conclusions

The two kinds of HCC cell lines used in this study were Group I, the more epithelial
hepatocyte like cells and Group II, the mesenchymal and metastatic cells. GP73 expression was
confirmed to be higher in all Group II lines compared to Group I HCC lines (Figure 36). Ecadherin, a cell-cell adhesion molecule plays a pivotal role in epithelial cell behavior and
suppression of cancer, and vimentin, a type III intermediate filament protein offers flexibility to
the cell and serves as a marker for EMT during metastatic progression. The expression of these
two markers studied in the Group I and Group II cell lines confirmed that Group I cell lines carry
the epithelial trait, and express the epithelial marker E-cadherin (Figure 37), and Group II cell
lines are invasive as seen by the invasion assay, and express the EMT marker Vimentin (Figure
38).
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Figure 43: GP73 knockdown increases cell migration and invasiveness of Group I cell line Huh7. A)
Percent invasion and Invasion index of Huh7 GP1 knockdown line compared to its control. B) Graph
representing the average number of cells migrating (on the left) and invading (on the right) from 12
different counts with standard deviation bars. * indicates that p-value is < 0.050 and thus the difference
can be considered significant. C) Microscopic images at 400 X magnification.
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SK Hep-1 GP73 Over-expression:
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Figure 44: GP73 over-expression does not change cell migration and invasiveness of a Group II cell
line SK Hep-1. A) Percent invasion and Invasion index of SK Hep-1 hGOLM1 line compared to its
control. B) Graph representing the average number of cells migrating (on the left) and invading (on the
right) from 12 different counts with standard deviation bars. The difference is not statistically significant.
C) Microscopic images at 400 X magnification.
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SK Hep-1 GP73 knockdown:
A
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Figure 45: GP73 knockdown increases cell migration and invasiveness of a Group II cell line SK
Hep-1. A) Percent invasion and Invasion index of SK Hep-1 GP4.3 knockdown line compared to its
control. B) Graph representing the average number of cells migrating (on the left) and invading (on the
right) from 12 different counts with standard deviation bars. * indicates that p-value is < 0.050 and thus
the difference can be considered significant. C) Microscopic images at 400 X magnification.
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Hep3B GP73 Over-expression:
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Figure 46: GP73 over-expression increases cell migration and invasiveness of a Group I cell line
Hep3B. A) Percent invasion and Invasion index of Hep3B GP73 line compared to its control. B) Graph
representing the average number of cells migrating (on the left) and invading (on the right) from 12
different counts with standard deviation bars. * indicates that p-value is < 0.050 and thus the difference
can be considered significant. C) Microscopic images at 400 X magnification.
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As hypothesized, Group I cell line showed a decrease in E-cadherin expression and an
increase in vimentin expression upon over-expression of GP73 and vice versa when GP73 was
silenced (Figures 41 and 42). However, no such change in E-cadherin was observed in Group II
transfectant cell lines and vimentin expression was increased in both Group II over-expressing
and knock down cell lines (Figures 41 and 42). Contrary to expectations, migration and
invasiveness of both Group I and Group II cell lines increased when GP73 was knocked down
(Figures 43 and 45). Also, as hypothesized, over-expression of GP73 in Group I cell line Hep3B
resulted in increased migration and invasion (Figure 44), but no such change was observed in the
Group II over-expressing cell line SK Hep-1 (Figure 46); perhaps because GP73 expression and
its associated programs are already "on" in Group II HCC, and additional GP73 doses fail to
further affect metastatic behavior.

GP73 AND LIVER INFLAMMATION

Introduction

GP73 expression is known to be enhanced in several liver diseases apart from HCC such
as acute cell hepatitis, chronic viral hepatitis (HCV and HBV infection), and hepatic Wilson's
disease; however, the role it plays in these liver diseases is still unknown. It has been speculated
to play an important role in the process of inflammation which is an integral part of these liver
diseases. Hepatocellular inflammation, injury and fibrosis were shown to be the driving forces
for increased GP73 expression in Wilson's disease (Wright, Huster, et al., 2009). Adenoviral
infection induces GP73 expression via CtBP interaction domain of adenoviral early region 1A
which was able to activate the GOLM1 promoter (Raleigh D. Kladney, Tollefson, Wold, &
Fimmel, 2002). Another study showed high levels of GP73 in HepG2.2.15 cells (a cell line that
supports active HBV replication), but is absent in HepG2T14.1 cells (an HBV-transfected cell
line that does not support HBV replication) and in HBV-free HepG2 cells (Liu, Zou, Zhu, Hu, &
Zeng, 2013). GP73 shows a striking sensitivity and specificity for diagnosing significant fibrosis
and severe inflammation in patients with chronic HBV infections. GP73 mediates hepatic stellate
cell proliferation and also appears to be a contributor to fibrogenesis in these patients (Wei et al.,
2013). A recent study in HCV (Hepatitis C virus) infected HCC cell line showed that coiled-coil
domain of GP73 was required to increase HCV secretion via interaction with apolipoprotein E,
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an identified host factor that assists in HCV secretion (Hu et al., 2014). Additionally,
inflammatory cytokines such as Interleukin-6 have been implicated in induction of GP73
expression as the liver's response to acute injury (Liang et al., 2012). Such cytokines like IL-1β
have also been shown in a recent study to upregulate GP73 expression via ESE-1, an epithelium
specific transcription factor, which directly binds and activates its promoter in HCC samples (F.
Wang et al., 2014). Thus, the role of GP73 has been established and continues to evolve in viral
infection and liver inflammation.
Scientific Aims

The role of GP73 in viral infection, HCV-induced HCC, fibrosis and inflammation has
already been established in humans. Therefore, it was hypothesized that HCV infected Huh7 cell
line would show an enhanced GP73 expression on Day 5-6 (HCV assembly and packaging) of
HCV infection and so would the fibrotic and cancerous tissues compared to normal liver; reestablishing the role GP73 plays in inflammation in mice. The corresponding specific aims
proposed to test this hypothesis were:
1. To study expression of several genes including GP73 and amino acid transporters such as
ASCT2 and LAT1 in collaboration with Dr. Gulam Warris (Rosalind Franklin University,
Medical School) on HCV infected Huh7 cell line (a Group I epithelial HCC line).
2. To analyze GP73 expression in mouse liver tissues treated with CCl4 (induces liver fibrosis)
over a period of 8-18 weeks and in HCC cell lines that have originated from patients with HBV
and HCV infection (Huh1 and Huh7 respectively).
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Results

GP73 expression during Liver Injury

Fibrotic and tumor mouse tissues obtained from Dr. Bryan Fuchs (Massachusetts General
Hospital, Harvard Medical School) were processed to obtain RNA which was followed by cDNA
preparation and qPCR to compare the expression level of GP73. Chronic CCl4 treatment induces
liver inflammation leading to fibrosis and ultimately HCC.
The following samples were used from strain A/J mice:
Normal Liver from Olive Oil Controls
001= Gavaged 0.1 ml olive oil 3X weekly for 8 weeks
002= Gavaged 0.1 ml olive oil 3X weekly for 8 weeks
003= Gavaged 0.1 ml olive oil 3X weekly for 8 weeks
006= Gavaged 0.1 ml olive oil 3X weekly for 12 weeks
007= Gavaged 0.1 ml olive oil 3X weekly for 12 weeks
008= Gavaged 0.1 ml olive oil 3X weekly for 12 weeks
0011= Gavaged 0.1 ml olive oil 3X weekly for 18 weeks
0013= Gavaged 0.1 ml olive oil 3X weekly for 18 weeks
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Fibrotic Tissue from CCl4 Animals
CT4= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 8 weeks
CT5= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 8 weeks
CT8= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 12 weeks
CT9= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 12 weeks
CT10= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 12 weeks
CT18= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 18 weeks
CT19= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 18 weeks
CT34= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 18 weeks
Tumor Tissue from CCl4 Animals
CT14 tumor= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 18 weeks
CT34 tumor= Gavaged 0.1 ml of 40% CCl4 in olive oil 3X weekly for 18 weeks
The results showed a two to seventeen fold increase in GP73 mRNA levels in the fibrotic
and tumorigenic mouse liver tissues compared to a set of eight normal mouse liver tissues
(Figure 47).
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Figure 47: Change in GOLM1 mRNA expression levels in CCl4 treated mouse livers. A 2 to 16
higher fold change is observed in CCl4 treated fibrotic and tumor mouse liver tissue samples compared to
a set of eight normal mouse liver tissue samples. Graph comparing geometric mean of GOLM1 mRNA
expression levels of fibrotic and tumor tissues normalized against control samples (eight normal liver
tissues) with CANX and GAPDH as reference genes in two separate qPCR run in triplicates.

HCV infected Huh7 cell line and GP73 expression

Huh7 cells were infected by HCV at Rosalind Franklin University, and were harvested on
each subsequent day post infection for 7 days. Frozen cell pellets were obtained from Dr. Gulam
Warris. The control Huh7 line was prepared by infecting with supernatant from HCV replication
defective cells. Cells were processed with 100 μl of 1X lysis buffer to extract total cellular
protein which was then size separated and blotted for GP73, ASCT2 and LAT1.
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HCV life cycle involves the following stages:
1- 15-30 minutes for HCV binding to cell surface receptors.
2- 4-6 hours for HCV internalization (entry) into hepatocytes.
3- 12-24 hours (HCV translation) for making all viral proteins
4- 36 hours (Replication begins)
5- Day 5-6 (HCV assembly and packaging)
6- Day 6 onwards infectious HCV releases.
The results showed that HCV affected GP73, ASCT2 and LAT1 expression on day 7
post-infection (Figures 48 - 50).

Figure 48: GP73 expression increases on Day 7 post-HCV infection. On the western blot on the left,
"A" are bands of GP73 and "B" are bands for the loading control Histone H3. The graph on the right
shows an Image J analysis of the western blot bands for analyzing GP73 expression with progression of
HCV infection.
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Figure 49: ASCT2 expression gradually increases as HCV infection progresses. On the western blot
on the left, "A" are bands of ASCT2 and "B" are bands for the loading control Histone H3. The graph on
the right shows an Image J analysis of the western blot bands for analyzing ASCT2 expression with
progression of HCV infection.

Figure 50: LAT1 expression increases of Day 7 post-HCV infection. On the western blot on the left,
"A" are bands of LAT1 and "B" are bands for the loading control Histone H3. The graph on the right
shows an Image J analysis of the western blot bands for analyzing LAT1 expression with progression of
HCV infection.

Conclusions

Transformation and growth of malignant tissues have often been known as wound
healing gone wrong (Arnold, Opdenaker, Flynn, & Sims-Mourtada, 2015). Mechanisms involved
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in wound healing in addition to chronic inflammation have been reported to enhance cancer stem
cell populations, causing local and systemic recurrences (Arnold et al., 2015). GP73 overexpression due to liver injury and inflammation has been repeatedly noted in hepatitis infections,
Wilson's disease, NASH etc. In this study, mice treated with carbon tetrachloride (CCl4) were
analyzed for GP73 expression in their liver generously provided by Dr. Bryan Fuchs. CCl4
targets the peri-venous hepatocytes more than the peri-portal and these results show a definite
increase in GP73 expression, up to 25-fold change in 18 weeks CCl4-treated fibrotic tissues
(Figures 48 - 50), indicating the strength of GP73 as a biomarker for liver injury and potential
progression to HCC.
Huh7 appears to be the only cell line capable of being infected by HCV, perhaps because
Huh7 comes from an HCC patient with a history of HCV infection and therefore has the
appropriate receptors to accept the virus. Our collaboration with Dr. Gulam Waris provided us
with HCV infected Huh7 cell lines at different time points post-infection. It was observed that
HCV infection of Huh7 results in gradual increase in ASCT2 and a noteworthy increase in LAT1
and GP73 on Day 7 (Figures 48 and 50) which involves the release of infectious HCV particles
from the cells. GP73 being a Golgi protein could play an important role in packaging and
secretion of HCV particles. The gradual increase in ASCT2 (Figure 49) could indicate glutamine
transporters maybe required at enhanced levels in HCV particle production.

LIVER-SPECIFIC GP73 KNOCKOUT MICE

Introduction

The Cre-LoxP conditional knockout system was used with Albumin promoter linked Cre
recombinase gene to ensure expression of the enzyme specifically in the liver since albumin
promoter is highly active in hepatocytes (Kos, 2004). The CRE recombinase then results in the
deletion of exon 3 (containing the start site) of GOLM1 gene placed in between two loxP sites
oriented in the same direction in the liver cells (Figure 51).

Figure 51: The Alb-Cre LoxP conditional knockout system.
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A liver-specific GOLM1 null mutation in mice has the potential to serve as a system for
studying the role of GP73 in HCC. Previous studies using transgenic mouse models with a
globally expressed and truncated GOLM1 provided evidence for its critical role in maintaining
the integrity of renal and hepatic tissues (Wright, Yong, Picken, Rockey, & Fimmel, 2009).
However, a global truncation mutation might reflect phenotypic changes in kidney and liver that
may not be indicative of the role of the protein, might reflect a model-specific dominant negative
mutation not reflective of its role in human disease and also may be due to complex remote
interactions between several tissues (Fimmel & Wright, 2009). So, the effects of hepatocytespecific deletion of GOLM1 were assessed to understand the role GP73 protein could potentially
play in the normal liver.
Scientific Aims

It was hypothesized that a liver-specific GP73 knockout mouse model would overcome
the above mentioned limitations and provide results with potential in translational research for
liver inflammation and carcinogenesis. The specific aims of this study were:
1. To develop a hepatocyte-specific GOLM1 knockout (LSKO) mouse model.
2. To assess the gross phenotype of GOLM1 LSKO mice.
3. To provide a tool to study the role of GP73 in liver inflammation and hepatocarcinogenesis.
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Results

Genotyping (Confirmation of genotype)

PCR analysis from tail DNA revealed the presence or absence of Cre (Figure 52) and the
two loxP sites (Figure 53) resulting in a colony consisting of control and experimental mice with
the genotypes shown in Table 5.

Table 5: Number of experimental (LSKO) and control mice obtained from
57 breeding experiments.
-/Fl/Fl
+
Cre GOLM1
Cre GOLM1 Wt/Wt
Cre+ GOLM1 Fl/Wt
Cre+ GOLM1Fl/Fl
Control

Control

70

65

Heterozygous LSKO Homozygous LSKO
110

25

Figure 52: Gel image for a genotyping PCR for Cre using Cre F and Cre R primers resulting in a 256
bp band.
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Figure 53: Gel image for a genotyping PCR for LoxP sites using LoxP and NeoDelR primers (on the
left) resulting in a 1926 bp band for flox and LoxP and SDL2 primers (on the right) resulting in a 383 bp
band for flox.

Phenotypic Analysis

Male and female mice aged 15 and 16 months old were weighed before being euthanized.
These end-point body weights of age and sex matched experimental and control mice were
compared (Figure 54). Even though an initial assessment showed an increase in body weight
with liver GP73 knockout, as per the standard deviations and the T-test these changes were found
to be "not significant".
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Figure 54: Body weight comparisons of control and LSKO mice. No significant changes (p-value >
0.050) in body weights due to GP73 knockout in hepatocytes of GP73flox/flox mice. Graph comparing body
weights of 2 age groups of female (A) and male (B) control and liver specific GP73 knockout mice.
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-/-

Liver abnormalities (Figure 55) were observed on 10 out of 40 control Cre GOLM1

Fl/Fl

mice and 4 out of 15 experimental Cre+ GOLM1Fl/Fl mice. Therefore, irrespective of GP73, 1 in 4
mice showed liver abnormalities, the nature of which will be confirmed with histopathology.

Figure 55: Macroscopic phenotypic analysis of mouse livers. Hepatomegaly, multifocal pitting (on the
left) and white multifocal coalescing patches (on the right) were grossly observed on livers of 1 in 4 mice
irrespective of GP73 presence.

Mortality: 5 out of 70 control Cre-/- GOLM1Fl/Fl mice and 1 out of 25 experimental Cre+
GOLM1Fl/Fl mice died of natural causes (due to old age). Therefore, irrespective of GP73, the
mortality rate was 1 in 5.
No differences were observes in breeding, behavior, pup mortality or appetite in the
experimental mice compared to the controls.
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Conclusions

GP73 deletion in hepatocytes does not appear to exert evident or detrimental effects in
mice. Although there is a trend observed in end-point body weights, we need to repeat the
experiments with greater power to achieve significance. Other factors such as old age and
enlarged livers or spleen might have affected the body weights. Colony health reports from the
sentinels ruled out viral and bacterial infections that could cause any liver abnormalities or affect
the study in any other way. Liver abnormalities and mortality in the mouse colony were not
affected by the presence or absence of GP73.

SUMMARY, DISCUSSION AND FUTURE DIRECTIONS

The results from this study revealed that GP73 may not be necessary but is sufficient to
induce EMT and metastasis and that it could potentially play a role in enhancing cell
proliferation in Group II cell lines. Tables 6, 7 and 8 summarize results from cell proliferation
and metastasis studies done on the 13 different HCC cell lines and the GP73 over-expressing and
silenced cell lines. The results obtained are context-specific because only one cell line from each
HCC group was used to over-express or silence GP73. The expression profile of a cell
(expression of ASCT2, LAT1, E-cadherin, vimentin) does not always translate into cell behavior
as there are many other physiological factors involved in the growth, proliferation, migration or
invasion of a cell that were not assessed in this study.
Table 6: Summary of GP73 transfected cell lines and their cell proliferation, glutamine and leucine
uptake, and ASCT2 and LAT1 expression. ↓ and ↑ indicate a decrease and increase respectively. ♦
indicates that the change is not significant.

Cell line

GP73
knock-in/
knockdown

Cell
Proliferation

Glutamine
uptake

ASCT2
expression

Leucine
uptake

LAT1
expression

SK Hep-1

↓

↓

↑

↑

↑

↑

SK Hep-1

↑

↑♦

↓

↓

No
change

↑

Huh7

↓

↑

↓

↓

↑

↓

Hep3B

↑

↓♦

↓

↑

↑

↑
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Table 7: Summary of expression of GP73, E-cadherin and vimentin in the 13 different HCC cell
lines along with their invasion assay results. √ indicates presence.
Cell line

GP73

E-cadherin

Hep3B

√

HepG2

√

Huh1

√

√

Huh7

√

√

PLC/PRF/5

√

Tong

√

Vimentin

Migration

Invasion

√
√

√

√

√

SK Hep-1

√

√

√

√

FOCUS

√

√

√

√

SNU449

√

√

√

√

SNU475

√

√

√

√

SNU387

√

√

√

SNU423

√

√

√

√

Mahlavu

√

√

√

√
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Table 8: Summary of GP73 transfected cell lines and their invasion assay results along with Ecadherin and Vimentin expression. ↓ and ↑ indicate a decrease and increase respectively. ♦ indicates
that the change is not statistically significant.

Cell line

GP73 knock-in/
knock-down

Migration

Invasion

E-cadherin
expression

Vimentin
expression

SK Hep-1

↓

↑

↑

no change

↑

SK Hep-1

↑

↓♦

↓♦

no change

↑

Huh7

↓

↑

↑

↑

↓

Hep3B

↑

↑

↑

↓

↑

Cells that endogenously express high levels of GP73 such as Huh7 and SK Hep-1
through the manipulations reported here show that GP73 is not necessary for metastasis as
silencing GP73 does not result in decreased invasiveness. GP73 appears to play a role other than
metastasis in cells that normally over-express GP73 - such as protein secretion or trafficking in
Huh7. Silencing GP73 also unencumbers Huh7 cell line to grow faster and invade more by
reducing the burden on Golgi bodies and endoplasmic reticulum to make and cycle GP73
through the trans-Golgi. Huh7 being the only cell line that can be infected by HCV, it is possible
that GP73 plays an important role in viral propagation in Group I cells. High GP73 levels on day
7 of HCV infection of Huh7 indicates a potential role of GP73 in secretion of viral particles. The
decrease in cell proliferation or growth in SK Hep-1 GP73 knockdown cell lines indicates that
GP73 plays a role more directed towards increasing the rate of proliferation and biomass instead
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of metastasis in Group II HCC cells. Therefore, in the context of a highly aggressive
mesenchymal cell line, where GP73 is geared more towards increasing proliferation rate and
biomass, when GP73 is silenced the cell switches from a more proliferative profile to a more
metastatic one - which does not necessarily involve active cell proliferation, but does involve
enhanced migration and invasion. Inside the liver tissue, such a loss of proliferative profile could
result in a signal cascade causing the cells to metastasize outside the home unit in search of
growth signals, thus reallocating resources such as glutamine and leucine to migration and
invasion of a cell. This metastasis occurs in a cell line with a mesenchymal background, hence an
EMT is not needed.
On the other hand, in epithelial liver carcinomas such as Hep3B, that do not normally
express GP73, over-expressing GP73 is sufficient to induce EMT and metastasis. The increase in
cell invasion and migration in Hep3B GP73 over-expressing cell line indicates that GP73 plays a
role more directed towards metastasis in Group I HCC cell lines, which explains why Group I
HCC cells expressing low GP73 are less invasive. Decreased E-cadherin expression and
increased vimentin expression in GP73 over-expressing Group I cell line indicates that GP73
plays a role in EMT, but is not indispensable.
GP73 is neither necessary nor sufficient to enhance rates of cell proliferation in Group I
HCC cell lines as seen by decreased rate of cell proliferation in GP73 over-expressing Hep3B
and enhanced cell proliferation rates in GP73 silenced Huh7. However, stable knockdown of
GP73 slows down proliferation rates and transient over-expression of GP73 in SK Hep-1
increases the proliferation rate indicating that GP73 is necessary for enhanced cell proliferation
in Group II HCC cell lines and could potentially even be sufficient to enhance rates of cell
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proliferation in Group II HCC cell lines. Also, more pronounced inhibition of cell growth or cell
death caused by rapamycin in GP73 expressing cell lines suggests that GP73 plays a role in the
mTOR signaling pathway crucial for promoting cell growth and reducing autophagy. Based on
these results, GP73 is proposed as a therapeutic target for advanced more aggressive HCC in
patients.
The relationship of GP73 and liver inflammation has already been established in previous
studies on human HCC patients. This relationship was re-established in mouse liver to illustrate
that mouse liver tumorigenesis is comparable to human HCC. Studies using CCl4 treated normal,
fibrotic and HCC liver tissues (from Dr. Fuchs) indicated a role for GP73 in liver injury which
involves liver inflammation. Considering the low expression of GP73 in hepatocytes in a normal
liver, we did not expect to see any difference between the control and liver-specific knockout at
this stage, however our goal to generate liver-specific GP73 knockout mice for future studies in
liver inflammation and HCC were met.
Future Directions
In vitro studies
With the development of more advanced tools of altering gene, future studies can
involve complete knockout of GP73 at the DNA level using the CRISPR-Cas system from
TransOMIC technologies and stable inducible over-expression of GP73 using the Tet-On 3G
Inducible Expression System (with mCherry) from Clontech laboratories in both Group I and
Group II cell lines. GP73 knock-out and over-expression in at least 3 Group I and Group II lines
might provide consistent results and can be followed by subcutaneous injection of these cells in
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immuno-deficient mice for tumorigenesis studies. We hypothesize that Group I GP73 overexpressing cell lines and Group II GP73 suppressed cell lines will be highly tumorigenic.
Analysis of factors involved in growth and apoptosis of cells and mTOR activity in GP73 overexpressing and knock down cell lines will help further elucidate the role of GP73. Lastly, HCV
infection of Huh7 GP73 knockdown cell lines will be assessed to examine the impact that loss of
GP73 has on viral propagation.
In vivo studies
Phenotypic analysis of the mice at the histological and serum biochemical levels
remains to be done. Liver and kidney tissues fixed in formalin processed by core microscopy
technician, Lori Bross (NIU, Department of Biological Sciences) and embedded in paraffin
blocks, sectioned and placed on slides will be sent to Dr. Nora Joseph, liver pathologist at
Northshore University for H & E staining and single-blind examination of the liver and tissue
histology. Blood collected from mice was allowed to clot at room temperature for 30 minutes
and centrifuged at 2000 x g for 10 minutes to obtain serum, and stored in a clean tube at 4oC. The
serum samples will be sent to IDEXX BioResearch (University of Missouri, School of
Veterinary Medicine) for a panel of liver function tests including albumin, alkaline phosphatase,
alanine aminotransferase, aspartate aminotransferase, total bilirubin and total protein.
In the liver-specific GP73 knockout mice that have been generated, HCC will be
chemically induced. It is a favorable model for research as we need HCC to develop in a natural
background of liver damage (Heindryckx, Colle, & Van Vlierberghe, 2009) to properly assess
the impact of liver-specific GP73 knockout on the progression of cancer. A two stage model in
which N-nitrosodiethylamine (DEN) will be used as an initiator and phenobarbitol as a
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promoting agent would serve as a good model for HCC development in these mice. We
hypothesize that GP73 knockout in hepatocytes prevents HCC from metastasizing.
In conclusion, GP73 has only recently come to the limelight with its probable role in cell
proliferation and metastasis. Our study like the others recently published strongly imply that
GP73 is not only an effective serum biomarker for HCC but is also a potential therapeutic target
for treatment of advanced HCC, and its role in liver cancer cells likely changes as cancers
advance and progress, leading to context-specific impacts on cellular behavior.

REFERENCES

Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006). Sorafenib (BAY 43-9006, Nexavar), a dualaction inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases
VEGFR/PDGFR in tumor vasculature. Methods Enzymol, 407, 597-612. doi: 10.1016/S00766879(05)07047-3
Aledo, J. C. (2004). Glutamine breakdown in rapidly dividing cells: waste or investment? Bioessays,
26(7), 778-785. doi: 10.1002/bies.20063
Arnold, K. M., Opdenaker, L. M., Flynn, D., & Sims-Mourtada, J. (2015). Wound healing and cancer
stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth
Metastasis, 8, 1-13. doi: 10.4137/CGM.S11286
Ashworth, R. E., & Wu, J. (2014). Mammalian target of rapamycin inhibition in hepatocellular
carcinoma. World J Hepatol, 6(11), 776-782. doi: 10.4254/wjh.v6.i11.776
Bachert, C., Fimmel, C., & Linstedt, A. D. (2007). Endosomal trafficking and proprotein convertase
cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic, 8(10),
1415-1423. doi: 10.1111/j.1600-0854.2007.00621.x
Baird, F. E., Beattie, K. J., Hyde, A. R., Ganapathy, V., Rennie, M. J., & Taylor, P. M. (2004).
Bidirectional substrate fluxes through the system N (SNAT5) glutamine transporter may
determine net glutamine flux in rat liver. J Physiol, 559(Pt 2), 367-381. doi:
10.1113/jphysiol.2003.060293
Bao, Y. X., Cao, Q., Yang, Y., Mao, R., Xiao, L., Zhang, H., . . . Wen, H. (2013). Expression and
prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition
(EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol, 8, 197. doi:
10.1186/1746-1596-8-197
Block, T. M., Comunale, M. A., Lowman, M., Steel, L. F., Romano, P. R., Fimmel, C., . . . Mehta, A. S.
(2005). Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver
cancer in woodchucks and humans. Proc Natl Acad Sci U S A, 102(3), 779-784. doi:
10.1073/pnas.0408928102
Bode, B. P., Fuchs, B. C., Hurley, B. P., Conroy, J. L., Suetterlin, J. E., Tanabe, K. K., . . . Souba, W. W.
(2002). Molecular and functional analysis of glutamine uptake in human hepatoma and liverderived cells. Am J Physiol Gastrointest Liver Physiol, 283(5), G1062-1073. doi:
10.1152/ajpgi.00031.2002

94
Boden, D., Pusch, O., Silbermann, R., Lee, F., Tucker, L., & Ramratnam, B. (2004). Enhanced gene
silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res, 32(3),
1154-1158. doi: 10.1093/nar/gkh278
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., . . . Wittwer, C. T. (2009).
The MIQE guidelines: minimum information for publication of quantitative real-time PCR
experiments. Clin Chem, 55(4), 611-622. doi: 10.1373/clinchem.2008.112797
Chen, L., Li, M., Li, Q., Wang, C. J., & Xie, S. Q. (2013). DKK1 promotes hepatocellular carcinoma cell
migration and invasion through beta-catenin/MMP7 signaling pathway. Mol Cancer, 12, 157. doi:
10.1186/1476-4598-12-157
Chen, X., Wang, Y., Tao, J., Shi, Y., Gai, X., Huang, F., . . . Zhang, H. (2015). mTORC1 Up-Regulates
GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of
Xenograft Tumors in Mice. Gastroenterology, 149(3), 741-752 e714. doi:
10.1053/j.gastro.2015.05.005
Dai, M., Chen, X., Liu, X., Peng, Z., Meng, J., & Dai, S. (2015). Diagnostic Value of the Combination of
Golgi Protein 73 and Alpha-Fetoprotein in Hepatocellular Carcinoma: A Meta-Analysis. PLoS
One, 10(10), e0140067. doi: 10.1371/journal.pone.0140067
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B.
(2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that
exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A, 104(49),
19345-19350. doi: 10.1073/pnas.0709747104
Duran, R. V., Oppliger, W., Robitaille, A. M., Heiserich, L., Skendaj, R., Gottlieb, E., & Hall, M. N.
(2012). Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell, 47(3), 349-358. doi:
10.1016/j.molcel.2012.05.043
Fimmel, C. J., & Wright, L. (2009). Golgi protein 73 as a biomarker of hepatocellular cancer:
development of a quantitative serum assay and expression studies in hepatic and extrahepatic
malignancies. Hepatology, 49(5), 1421-1423. doi: 10.1002/hep.22994
Fuchs, B. C., & Bode, B. P. (2005). Amino acid transporters ASCT2 and LAT1 in cancer: partners in
crime? Semin Cancer Biol, 15(4), 254-266. doi: 10.1016/j.semcancer.2005.04.005
Fuchs, B. C., Finger, R. E., Onan, M. C., & Bode, B. P. (2007). ASCT2 silencing regulates mammalian
target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell
Physiol, 293(1), C55-63. doi: 10.1152/ajpcell.00330.2006
Fuchs, B. C., Perez, J. C., Suetterlin, J. E., Chaudhry, S. B., & Bode, B. P. (2004). Inducible antisense
RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells.
Am J Physiol Gastrointest Liver Physiol, 286(3), G467-478. doi: 10.1152/ajpgi.00344.2003
Ganapathy, V., Thangaraju, M., & Prasad, P. D. (2009). Nutrient transporters in cancer: relevance to
Warburg hypothesis and beyond. Pharmacol Ther, 121(1), 29-40. doi:
10.1016/j.pharmthera.2008.09.005

95
Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C., & Avruch, J. (1998). Amino acid
sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector
mechanism. J Biol Chem, 273(23), 14484-14494.
Hayat, M. J., Howlader, N., Reichman, M. E., & Edwards, B. K. (2007). Cancer statistics, trends, and
multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER)
Program. Oncologist, 12(1), 20-37. doi: 10.1634/theoncologist.12-1-20
Heindryckx, F., Colle, I., & Van Vlierberghe, H. (2009). Experimental mouse models for hepatocellular
carcinoma research. Int J Exp Pathol, 90(4), 367-386. doi: 10.1111/j.1365-2613.2009.00656.x
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013). Glutamine and cancer: cell biology,
physiology, and clinical opportunities. J Clin Invest, 123(9), 3678-3684. doi: 10.1172/JCI69600
Hoshida, Y., Nijman, S. M., Kobayashi, M., Chan, J. A., Brunet, J. P., Chiang, D. Y., . . . Golub, T. R.
(2009). Integrative transcriptome analysis reveals common molecular subclasses of human
hepatocellular carcinoma. Cancer Res, 69(18), 7385-7392. doi: 10.1158/0008-5472.CAN-091089
Hou, Y., Zou, Q., Ge, R., Shen, F., & Wang, Y. (2012). The critical role of CD133(+)CD44(+/high)
tumor cells in hematogenous metastasis of liver cancers. Cell Res, 22(1), 259-272. doi:
10.1038/cr.2011.139
Hu, L., Li, L., Xie, H., Gu, Y., & Peng, T. (2011). The Golgi localization of GOLPH2 (GP73/GOLM1) is
determined by the transmembrane and cytoplamic sequences. PLoS One, 6(11), e28207. doi:
10.1371/journal.pone.0028207
Hu, L., Yao, W., Wang, F., Rong, X., & Peng, T. (2014). GP73 is upregulated by hepatitis C virus (HCV)
infection and enhances HCV secretion. PLoS One, 9(3), e90553. doi:
10.1371/journal.pone.0090553
Iftikhar, R., Kladney, R. D., Havlioglu, N., Schmitt-Graff, A., Gusmirovic, I., Solomon, H., . . . Fimmel,
C. J. (2004). Disease- and cell-specific expression of GP73 in human liver disease. Am J
Gastroenterol, 99(6), 1087-1095. doi: 10.1111/j.1572-0241.2004.30572.x
Jiang, K., Li, W., Shang, S., Sun, L., Guo, K., Zhang, S., & Liu, Y. (2016). Aberrant expression of Golgi
protein 703 is indicative of a poor outcome in hepatocellular carcinoma. Oncol Rep. doi:
10.3892/or.2016.4601
Karra, D., & Dahm, R. (2010). Transfection techniques for neuronal cells. J Neurosci, 30(18), 6171-6177.
doi: 10.1523/JNEUROSCI.0183-10.2010
Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., . . . Sabatini,
D. M. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the
cell growth machinery. Cell, 110(2), 163-175.
Kladney, R. D., Bulla, G. A., Guo, L., Mason, A. L., Tollefson, A. E., Simon, D. J., . . . Fimmel, C. J.
(2000). GP73, a novel Golgi-localized protein upregulated by viral infection. Gene, 249(1-2), 5365.

96
Kladney, R. D., Tollefson, A. E., Wold, W. S. M., & Fimmel, C. J. (2002). Upregulation of the Golgi
Protein GP73 by Adenovirus Infection Requires the E1A CtBP Interaction Domain. Virology,
301(2), 236-246. doi: 10.1006/viro.2002.1523
Kojima, S., Enokida, H., Yoshino, H., Itesako, T., Chiyomaru, T., Kinoshita, T., . . . Seki, N. (2014). The
tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting
GOLM1 in prostate cancer. J Hum Genet, 59(2), 78-87. doi: 10.1038/jhg.2013.121
Kos, C. H. (2004). Cre/loxP system for generating tissue-specific knockout mouse models. Nutr Rev, 62(6
Pt 1), 243-246.
Lacey, J. M., & Wilmore, D. W. (1990). Is glutamine a conditionally essential amino acid? Nutr Rev,
48(8), 297-309.
Laplante, M., & Sabatini, D. M. (2013). Regulation of mTORC1 and its impact on gene expression at a
glance. J Cell Sci, 126(Pt 8), 1713-1719. doi: 10.1242/jcs.125773
Lee, J. S., & Thorgeirsson, S. S. (2002). Functional and genomic implications of global gene expression
profiles in cell lines from human hepatocellular cancer. Hepatology, 35(5), 1134-1143. doi:
10.1053/jhep.2002.33165
Li, L., Wen, L., Gong, Y., Mei, G., Liu, J., Chen, Y., & Peng, T. (2012). Xenopus as a model system for
the study of GOLPH2/GP73 function: Xenopus GOLPH2 is required for pronephros
development. PLoS One, 7(6), e38939. doi: 10.1371/journal.pone.0038939
Liang, H., Block, T. M., Wang, M., Nefsky, B., Long, R., Hafner, J., . . . Norton, P. A. (2012).
Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate
hepatocellular carcinoma biomarker GP73. Cancer Biomark, 11(4), 161-171. doi: 10.3233/CBM2012-00276
Liu, Y., Zhang, X., Sun, T., Jiang, J., Li, Y., Chen, M., . . . Zhou, L. (2016). Knockdown of golgi
phosphoprotein 2 inhibits hepatocellular carcinoma cell proliferation and motility. Oncotarget.
doi: 10.18632/oncotarget.7271
Liu, Y., Zou, Z., Zhu, B., Hu, Z., & Zeng, P. (2013). CXCL10 decreases GP73 expression in hepatoma
cells at the early stage of hepatitis C virus (HCV) infection. Int J Mol Sci, 14(12), 24230-24241.
doi: 10.3390/ijms141224230
Lynch, C. J. (2001). Role of leucine in the regulation of mTOR by amino acids: revelations from
structure-activity studies. J Nutr, 131(3), 861S-865S.
Marrero, J. A., Romano, P. R., Nikolaeva, O., Steel, L., Mehta, A., Fimmel, C. J., . . . Block, T. M.
(2005). GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular
carcinoma. J Hepatol, 43(6), 1007-1012. doi: 10.1016/j.jhep.2005.05.028
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., . . . Murphy, L. O. (2009).
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell, 136(3), 521-534.
doi: 10.1016/j.cell.2008.11.044

97
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J Clin,
55(2), 74-108.
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., . . . Horwitz, A. R.
(2003). Cell migration: integrating signals from front to back. Science, 302(5651), 1704-1709.
doi: 10.1126/science.1092053
Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., . . .
Sabatini, D. M. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive
and raptor-independent pathway that regulates the cytoskeleton. Curr Biol, 14(14), 1296-1302.
doi: 10.1016/j.cub.2004.06.054
Shao, Y. Y., Hsu, C. H., & Cheng, A. L. (2015). Predictive biomarkers of sorafenib efficacy in advanced
hepatocellular carcinoma: Are we getting there? World J Gastroenterol, 21(36), 10336-10347.
doi: 10.3748/wjg.v21.i36.10336
Shi, Y., Chen, J., Li, L., Sun, Z., Zen, L., Xu, S., . . . Zhang, L. (2011). A study of diagnostic value of
golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res
Treat, 10(3), 287-294.
Takeichi, M., Nimura, K., Mori, M., Nakagami, H., & Kaneda, Y. (2013). The transcription factors Tbx18
and Wt1 control the epicardial epithelial-mesenchymal transition through bi-directional
regulation of Slug in murine primary epicardial cells. PLoS One, 8(2), e57829. doi:
10.1371/journal.pone.0057829
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: the
metabolic requirements of cell proliferation. Science, 324(5930), 1029-1033. doi:
10.1126/science.1160809
Wang, F., Long, Q., Gong, Y., Hu, L., Zhang, H., Oettgen, P., & Peng, T. (2014). Epithelium-Specific
ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells. Cell Biosci, 4(1),
76. doi: 10.1186/2045-3701-4-76
Wang, Z., Jin, W., Jin, H., & Wang, X. (2014). mTOR in viral hepatitis and hepatocellular carcinoma:
function and treatment. Biomed Res Int, 2014, 735672. doi: 10.1155/2014/735672
Wei, H., Li, B., Zhang, R., Hao, X., Huang, Y., Qiao, Y., . . . Li, X. (2013). Serum GP73, a marker for
evaluating progression in patients with chronic HBV infections. PLoS One, 8(2), e53862. doi:
10.1371/journal.pone.0053862
Wright, L. M., Huster, D., Lutsenko, S., Wrba, F., Ferenci, P., & Fimmel, C. J. (2009). Hepatocyte GP73
expression in Wilson disease. J Hepatol, 51(3), 557-564. doi: 10.1016/j.jhep.2009.05.029
Wright, L. M., Yong, S., Picken, M. M., Rockey, D., & Fimmel, C. J. (2009). Decreased survival and
hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp
Pathol, 2(1), 34-47.
Zhang, H., Lin, W., Kannan, K., Luo, L., Li, J., Chao, P. W., . . . Yen, L. (2013). Aberrant chimeric RNA
GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human

98
esophageal squamous cell carcinoma. Oncotarget, 4(11), 2135-2143. doi:
10.18632/oncotarget.1465
Zhang, Y., Shen, Y., Cao, B., Yan, A., & Ji, H. (2015). Elevated expression levels of androgen receptors
and matrix metalloproteinase-2 and -9 in 30 cases of hepatocellular carcinoma compared with
adjacent tissues as predictors of cancer invasion and staging. Exp Ther Med, 9(3), 905-908. doi:
10.3892/etm.2014.2150
Zhang, Y. L., Zhang, Y. C., Han, W., Li, Y. M., Wang, G. N., Yuan, S., . . . Zhang, Y. W. (2014). Effect
of GP73 silencing on proliferation and apoptosis in hepatocellular cancer. World J Gastroenterol,
20(32), 11287-11296. doi: 10.3748/wjg.v20.i32.11287

